MXPA01003559A - Naphthalenecarboxamides as tachykinin receptor antagonists - Google Patents

Abstract

A compound having formula (I) wherein R1 is oxo, -ORa, -OC(=O)Rb;or (A);R2 is H;or R1 is -ORc and R2 is -ORd;or R1 and R2 together form -O(CH2)mO-;and any pharmaceutically-acceptable salt thereof along with their use in treating depression, anxiety, asthma, rheumatoid arthritis, Alzheimer's disease, cancer, schizophrenia, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, anxiety, emesis, Huntington's disease, psychoses including depression, hypertension, migraine, bladder hypermotility, or urticaria, along with methods of making the compounds and pharmaceutical compositions containing the compounds.

Description

NAFTALENOCARBOXAMIDAS AS ANTAGONISTS TAQUICININE RECEPTORS Background The mammalian neurokinins comprise a class of peptide neurotransmitters which are found in the central and peripheral nervous system. The three main neurokinins are substances P (SP), Neurokinin A (NKA) and Neurocinin B (NKB). There are also extended N-terminal forms of NKA. At least three types of receptors are known for the three major neurokinins. Based on their relative selectivities favoring the neurokinin antagonists SP, NKA, and NKB, the receptors are classified as neurokinin 1 (NK-.), Neurokinin 2 ( NK2), and neurokinin 3 (NK3), respectively. In the periphery, SP and NKA are located in afferent sensory neurons C, which are characterized by unmyelinated nerve endings known as C fibers, and are released by selective depolarization of these neurons, or selective stimulation of C fibers. C fibers are located in the epithelium of respiratory fibers, and tachykinins They are known to cause intense effects that clearly equate many of the symptoms seen in asthmatics. The effects of the release or introduction of tachykinins into mammalian airways include REF: 128136 bronchoconstriction,. increased microvascular permeability, vasodilatation, increased mucus secretion and activation of. mastocytic cells. Thus, tachykinins are implicated in the pathophysiology and airway hypersensitivity observed in asthmatics; and blocking the action of released tachykinins may be useful in the treatment of asthma and related conditions. A cyclopeptide antagonist (FK-224) selective for both NKi and NK2 receptors has demonstrated clinical efficacy in human patients suffering from asthma and chronic bronchitis. M. Ich-inose et al., Lancet, 1992, 340, 1248.

Description This invention relates to N-substituted naphthalenecarboxamide compounds by a substituted phenylpiperidinylbutyl group, to pharmaceutical compositions containing such compounds, as well as to their uses and processes for their preparation. These compounds antagonize the pharmacological actions of the endogenous neuropeptide tachykinins known as neurokinins, particularly the receptors neurokinin 1 (NKi), and neurokinin 2 (NK2). These compounds are useful at any time such antagonism is desired. Thus, such compounds are of value in the treatment of those diseases in which substances P and Neurocinin A are involved, for example in the treatment of asthma, anxiety, depression, emesis, urinary incontinence and related conditions. The N-substituted naphthalenecarboxamide compounds of the present invention show a high degree of antagonistic activity at the NKi and / or NK2 receptors. Additionally, by manipulation of the substituents on the naphthalene and piperidine rings of the formula (I), the percentage of activity at the NKi and NK2 receptors can be modified as desired, providing compounds that are predominantly active at the receptors. NKi or NK2 or providing compounds with a balanced activity and, as such, are particularly useful when the combined antagonism of both receptors is desired. In particular, the compounds of the present invention also possess a high degree of antagonism to NKi and / or NK2 by oral administration. Accordingly, the present invention provides the compounds of the general formula (I): (I) where: R1, on the one hand, has the formula wherein R7 and R8 are as defined below to give the general formula (la). (la) Intermediates, wherein R1 is oxo (= 0, which forms an aldehyde, -CHO) or R1 is 0Ra are also active compounds in their own ring. In a further aspect R1 is 0Ra wherein Ra is hydrogen or C6-6 alkyl. Preferably, Ra is hydrogen, methyl or ethyl and in particular Ra is hydrogen. In still an additional aspect Ra may represent an ester-forming group -C (= 0) Rb, wherein Rb is Ci-β alkyl, for example methyl, aryl for example phenyl or aryl C6-6 alkyl for example benzyl. R2 is H or R1 and R2 together represent the ketal of an aldehyde, for example of the formula (Rc0) CH (0Rd) - wherein Rc and Rd are independently selected from Ci-e alkyl, or together they form a chain of C2-4 methylene thus forming a dioxide ring. More suitably, Rc and Rd have the same value and are both methyl or both ethyl. When R1 is the piperidino species shown above, R2 is H. R3 is hydrogen or C6-6 alkyl, for example methyl, ethyl n-propyl or cyclopropyl. Preferably, R3 is methyl. R4, R5, and R6 are each, independently, hydroxy; cyano; nitro; trifluoromethoxy; trifluoromethyl; C6-alkylsulfonyl for example methylsulfonyl; halo for example chlorine, bromine, fluorine or iodine; C? -6 alkoxy for example methoxy, ethoxy or propoxy; Ci-e alkyl, for example methyl or ethyl; cyano C6-6 alkyl for example cyanomethyl, C2_6 alkenyl for example ethenyl, prop-1-enyl or prop-2-enyl; C2_6 alkynyl for example ethynyl; carboxy, C6-6 alkoxycarbonyl for example methoxycarbonyl; carbamoyl; C? _6 alkylcarbamoyl for example methylcarbamoyl or ethylcarbamoyl; di-C? _6 alkylcarbamoyl for example di-methylcarbamoyl; C? _6 alkanoyl for example acetyl or propionyl; C6-alkanoylamino for example acetylamino or propionylamino; aminosulfonyl; and C? -6 substituted alkyl for example methyl substituted by any of the aforementioned substituents herein, In addition, Re can be hydrogen.

Favorably, R 4 is C 6 -6 alkyl, for example methyl or ethyl; C6-alkoxy for example methoxy or ethoxy; or halo for example fluorine, chlorine, bromine or iodine. Preferably, R 4 is methyl, ethyl, methoxy, ethoxy or fluorine. More preferably, R is methoxy or ethyl, more preferably, methoxy. Preferably, R5 is cyano or nitro; more preferably, R5 is cyano. Preferably, R6 is hydrogen, methoxy, cyano or nitro. R7 is a phenyl or substituted phenyl group. * Substituted phenyl "means substituted in at least the ortho position by C? -6 alkylthio for example methylthio; C? -6 alkylsulfinyl for example methylsulfinyl, ethylsulfinyl or propylsulphinyl; C? -6 alkylsulfonyl for example methylsulfonyl or ethylsulfonyl; trifluoromethylthio; trifluoromethylsulfinyl; C6-alkanesulfonamido for example methanesulfonamido, C6-alkanoyl for example acetyl or propionyl, C6-alkoxycarbonyl for example methoxycarbonyl, succinic acid, carbamoyl, C6-alkylcarbamoyl for example methylcarbamoyl, di-C6-6 alkylcarbamoyl for example dimethylcarbamoyl; C6-6 alkoxy-C6-6 alkylcarbamoyl for example N-methoxy, N-ethylcarbamoyl;? -6 alkanoylamino for example acetylamino; ureido, C? -6 ureido for example methylureido; di-C? -6 alkylureide, for example dimethylureido, amino, C6-alkylamino, for example methylamino or ethylamino, or di-C6-alkylamino, for example dimethylamino, The preferred values for the ortho substituents are methylsulfinyl, ethylsulfinyl, propylsulfinyl, methylsulfonyl, trifluoromethylthio, trifluoromethylsulfinyl, methanesulfonamido, acetyl, methoxycarbonyl, succinamido, carbamoyl, ethylcarbamoyl, dimethylcarbamoyl, N-methoxy, N-methylcarbamoyl, acetylamino, ureido, methylureido, dimethylureido, amino, methylamino or dimethylamino. In particular, the ortho substituent is methylsulfinyl, methylsulfonyl, methylureido, dimethylureido, amino, methylamino or dimethylamino. Of these, methylsulfinyl is particularly preferred. The phenyl group substituted on R7 may optionally carry additional substituents. Suitable additional substituents, which are optional, for the phenyl ring substituted on R7 include Ci-e alkyl for example methyl or ethyl; C? -6 alkylthio for example methylthio or ethylthio; C? -6 alkylsulfinyl for example methylsulfinyl, ethylsulfinyl or propoxysulphinyl; C6-alkylsulfonyl, for example methylsulfonyl or ethylsulfonyl; C? -6 alkoxy for example methoxy, ethoxy or propoxy; halo for example bromine, fluorine, chlorine or iodine; carboxy; C? _6 alkoxycarbonyl for example methoxycarbonyl; C? -6 alkanoyl for example acetyl or propionyl; nitro; Not me; C? -6 alkylamino for example methylamino or ethylamino; di-C? -6 alkylamino wherein the alkyl groups may be the same or different, for example dimethylamino; trifluoromethyl; CF3 S (0) n where n is 0.1 or 2, for example, trifluoromethylthio, trifluoromethylsulfinyl or trifluoromethylsulfonyl; C6-alkanoylamino for example acetylamino or propionylamino; C? -6 alkylsulfonamido for example methylsulfonamido; ureido; C? -6 alkylureido for example methylureido (MeNHC (= 0) NH-), di-C? -6 alkylureido for example dimethylureido (Me2NC (=) NH-); carbamoyl; C? -6 alkylcarbamoyl for example methylcarbamoyl; di-C? _6 alkylcarbamoyl wherein the alkyl groups may be the same or different, for example dimethylcarbamoyl; and C? -6 alkyl for example methyl substituted by any of the aforementioned substituents. Additional preferred substituents for the substituted phenyl ring ortho, if present, are methyl, methoxy, acetyl, acetylamino, methoxycarbonyl, methanesulfonylamino, ethyl-sulfinyl, methylsulfonyl, trifluoromethyl, trifluoromethylthio, trifluoromethylsulfinyl, bromine, fluorine, chlorohydroxy, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, dimethylcarbamoylmethylureido and dimethylureido. In particular, these preferred substituents can be in the 4-position of the phenyl ring. Favorably, the ortho-substituted phenyl ring is not further substituted or substituted by up to three optional substituents. In particular the substituted phenyl ring ortho is not further substituted or is substituted at the 4-position, which is in the para-position to the bond with the piperidine ring, thus forming a 2,4-disubstituted phenyl group, preferably a phenyl group 4-substituted, 2-MeSO. Thus, a preferred class of compounds is that wherein R7 is of the formula (Ib): (Ib) wherein R9 is hydrogen, Ci-βalkoxy for example methoxy or ethoxy, halo for example bromine, chlorine or fluorine, d-β-alkylsulfinyl for example methylisulfinyl or carboxy. In particular R9 is hydrogen, C6-6 alkoxy or halo. More particularly R9 is hydrogen, methoxy or fluorine. The compounds of the invention have a number of chiral centers. It is preferred that the ortho-methylsulfinyl substituent, if present, have the stereochemistry shown in the formula (le): (le) R is hydrogen; hydroxy; C? -6 alkoxy for example methoxy or ethoxy; C? _6 alkanoyloxy for example acetyloxy or propionyloxy; C? -6 alkanoyl for example acetyl or propionyl; Ci-βalkoxycarbonyl for example methoxycarbonyl or ethoxycarbonyl; Ci-β-alkanoylamino for example acetylamino; C? -6 alkyl for example methyl or ethyl; Carbamoyl; C? _6 alkylcarbamoyl for example methylcarbamoyl or ethylcarbamoyl or di-Ci-e alkylcarbamoyl for example dimethylcarbamoyl. Preferably R8 is hydrogen, hydroxy, methoxycarbonyl, methylcarbamoyl or dimethylcarbamoyl. More preferably R8 is hydrogen or hydroxy; more preferably R8 is hydrogen. The compounds of the present invention possess a number of chiral centers, in -CH (Ph-X ^ X2) -, and possibly in optional substituents (for example the MeSO- substituent) in or (or both) of the phenyl groups and naft-1-yl. The present invention covers all isomers, diastereoisomers and mixtures thereof which antagonize NKi and / or NK2. The preferred configuration in -CH (Ph-X ^ X2) - is shown in the formula (Id) below: (Id) X1 and X2 are independently hydrogen or halo, provided that at least one of X1 or X2 is halo. Favorably, X1 and X2 are both chlorine. In a preferred aspect Ph-X1, X2 is 3,4-dichlorophenyl. A preferred class of compounds is that of formula (II): wherein R3 is as defined hereinbefore and R4-R6 are selected from hydrogen, cyano, nitro, methoxy and fluorine. In a particular aspect, in the compounds of the formula (II), R9 is hydrogen, methoxy or fluorine, R4 is hydrogen or fluorine, R6 is hydrogen, and R5 is cyano or nitro. In another particular aspect, R3 is hydrogen, methoxy or fluorine, R4 and R5 are hydrogen, and R6 is cyano or nitro. In a further particular aspect, R9 is hydrogen, methoxy or fluorine, R4 is methoxy, R6 is hydrogen, and R5 is cyano or nitro. The most preferred structures are The particular compounds of this invention are provided as the Examples below. Cp-z alkyl, unless otherwise specified, means an alkyl chain containing a minimum Y of total carbon atoms and a maximum Z of total carbon atoms. These alkyl chains can be branched or unbranched, cyclic, acyclic or a combination of cyclics and acyclics. For example, the following substituent will be included in the general description * C4-7 alkyl ": / The pharmaceutically acceptable salts can be prepared from the corresponding acid in conventional manner. The non-pharmaceutically acceptable salts may be useful as intermediates and as such are another aspect of the present invention. The compounds of the present invention are capable of forming salts with various organic and inorganic acids and bases and such salts are also within the scope of this invention. Examples of such acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bisulfate, butyrate, camforate, camphorsulfonate, citrate, cyclohexyl, sulfamate, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethyl sulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxyalate, lactate, malate, maleate, methanesulfonate, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, phenylacetate, phosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfanilate, sulfate, tartrate, tosylate (p-toluenesulfonate), and undecanoate. Basic salts include ammonium salts, salts of alkali metals such as sodium, lithium and potassium salts, salts of alkaline rare earth metals such as aluminum, calcium and magnesium salts, salts with organic bases such as salts of dicyclohexylamine, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, ornithine, and the like. Also basic groups containing nitrogen can be converted to quaternaries with agents such as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl halides; dialkyl sulfates such as dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl halides; aralkyl halides such as benzyl bromide and others. Non-toxic physiologically acceptable salts are preferred, although other salts are also useful, such as in the isolation or purification of the product. The salts can be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed in vacuo or by cold drying or by exchange of anions of an existing salt with another anion in a suitable ion exchange resin.

In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for therapeutic treatment (including prophylactic treatment) of mammals including humans, it is usually formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutical compositions of this invention can be administered in standard manners for the condition of the disease to be treated, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal administration or by inhalation or insufflation. For these purposes the compounds of this invention can be formulated by means known in the art in the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, powders. finely divided or aerosols or nebulizers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions. In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more valuable pharmacological agents in the treatment of one or more disease conditions referred to herein. . The pharmaceutical compositions of this invention will be administered in a normal manner to humans so that, for example, a daily dose of 0.01 to 25 mg / kg of body weight (and preferably 0.1 to 5 mg / kg of body weight) is received. This daily dose can be given in divided doses as necessary, the precise amount of the compound received and the route of administration depends on the weight, age and sex of the patient to be treated and the particular disease condition to be treated in accordance with the principles known in the art. Typically dosage forms per unit will contain from about 1 mg to 500 mg of a compound of this invention. For example, a tablet or capsule for oral administration can conveniently contain above 250 mg (and typically 5 to 100 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof. In another example, for administration by inhalation, a compound of the formula (I) or a pharmaceutically acceptable salt thereof can be administered in a daily dose range of 5 to 100 mg, in a single dose or divided in two to four doses daily In a further example, for administration by intravenous or intramuscular injection or infusion, a sterile solution or suspension containing above 10% w / w (and typically 5% w / w) of a compound of the formula can be used. (I) or a pharmaceutically acceptable salt thereof. Therefore in a further aspect, the present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof for use in a method of therapeutic treatment of the human or animal body. In yet a further aspect the present invention provides a method of treating a disease condition wherein antagonism of the NKi and / or NK2 receptors which comprises the administration to a warm-blooded animal of an effective amount of a compound is beneficial. of the formula (I) or a pharmaceutically acceptable salt thereof. The present invention also provides the use of a compound of the formula (I) of a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in a disease condition wherein antagonism of the NKi and / or NK2 receptors is beneficial. . The compounds of the formula (I) and their pharmaceutically acceptable salts can be made by processes as described and exemplified herein and by processes similar to these and by processes known in the prior art. If they are not commercially available, the initiator materials for these processes can be made by methods that are selected from the prior art using techniques that are similar or analogous to the synthesis of known compounds. In another aspect the present invention provides a process for the preparation of a compound of the formula (I) of a pharmaceutically acceptable salt thereof which process comprises: a) reacting a compound of the formula (III) with a compound of the formula (IV): (III) (IV) wherein from R3 to R8, X1 and X2 are as defined above; and L and L 'are the reductive amination groups of the compounds of the formula (III) and (IV) which form an N-C bond; or b) reacting a compound of the formula (V) with a compound of the formula (VI): (V) (VI) wherein R3 through R8 and X1 and X2 are as defined above; and L "is a residual group; where any other functional group is protected, if necessary, and: i) removal of any protection group; ii) optional formation of a pharmaceutically acceptable salt. Protection groups can generally be chosen from any of the groups described in the literature or known by experienced chemists as appropriate for the protection of the group in question, and can be introduced and removed by conventional methods, see for example Protecting Groups in Organic Chemistry; Theodora Greene. The removal methods are chosen such as to effect the removal of the protection group with the least alteration of the groups in another part of the molecule. It will also be appreciated that some of the various optional substituents on the compounds of the formula (I) can be introduced by standard aromatic substitution reactions or generated by conventional modifications of functional group either prior to or immediately after the processes described above. Reactants and reaction conditions for such processes are well known in the chemical art. The compounds of the formula (III) and (IV) are reacted under reductive amination conditions. Typically in the compounds of the formula (III) L is hydrogen. Typically in the compounds of the formula (IV) L 'is an oxo group forming an aldehyde moiety. The reaction is carried out typically at a non-extreme temperature, for example from 0 to 100 ° C, suitably at room temperature in a substantially inert solvent for example dichloromethane. Typically, reducing agents include borohydrides such as sodium cyanoborohydride. The compounds of the formula (III) are known or prepared in a conventional manner. The compounds of the formula (IV) can be prepared, for example, by the reaction of a compound of the formula (VI) with a compound of the formula (VII): (vil) wherein R3, L ', X1 and X2 are as defined above under conventional acylation conditions.

The compounds of the formula (V) and (VI) can be reacted under conventional acylation conditions wherein is an acid or an activated acid derivative. Such activated acid derivatives are well known in the literature. These can be formed in situ from the acid or can be prepared, isolated and subsequently reacted.

Typically L '' is chlorine with which it forms the acid chloride. Typically the acylation reaction is carried out in the presence of a non-nucleophilic base, for example, diisopropylethylamine, in an inert solvent substantially at a non-extreme temperature. The compounds of the formula (VII) are known or can be prepared in a conventional manner. Certain compounds of the formula (IV) and (VI) are novel and form part of the present invention. Particularly novel are the compounds of the formula (VI) wherein the naphth-1-yl group is replaced by a methoxy group in the 2-position and by a cyano group in the 3-position. Accordingly, in another aspect the present invention provides a compound of the formula (VIII): (VIII) where L "is found as defined above; preferably L "is hydrogen or a residual group such as chlorine. In another aspect the present invention provides a compound of the formula (IX): (IX) wherein R3, X1, X2 and L 'are as defined above. It is well known in the art how to prepare optically active forms (e.g., by resolution of the racemic form or by the synthesis of optically active initiator materials) and how to determine the properties of NKi and NK2 antagonists by standard tests known in the art and those described below. Some individual compounds within the scope of this invention may contain double bonds. Representations of the double bonds in this invention are proposed to include both the E-isomer and the Z-isomer of the double bond. Additionally, some species within the scope of this invention may contain one or more asymmetric centers. This invention includes the use of any of optically pure stereoisomers as well as any combination of stereoisomers.

The following biological methods, data and Examples serve to illustrate and further describe the invention. The utility of a compound of the invention or a pharmaceutically acceptable salt thereof (hereinafter collectively referred to as a "compound") can be demonstrated by standard tests and clinical studies, including those disclosed in the publications described below.

Receptor Binding Assay SP (Test A) The ability of a compound of the invention to antagonize SP binding to the NKi receptor can be demonstrated using a test using the human NK- receptor expressed in mouse erythroleukemia (MEL) cells. The human NKL receptor was isolated and characterized as described in: B. Hopkins, et al. Isolation and characterization of the human lung NKL receptor cDNA "Biochem Biophys, Res. Comm., 1991, 180, 1110-1117, and the NKi receptor was expressed in Mouse Erythroleukemia (MEL) cells using a procedure similar to that described in test B below.

Neurokinin A Receptor Binding Assay (NKA) (Test B) The ability of a compound of the invention to antagonize the binding of NKA to the NK2 receptor can be demonstrated using an assay using the human NK2 receptor expressed in Erythroleukemia cells of Mouse (MEL), as described in: Aharony, D., et al. Isolation and Pharmacological Characterization of a Hampster Neurokinin A cDNA Receptor "Molecular Pharmacology, 1994, 45, 9-19. The selectivity of a compound for binding to NKi and NK2 receptors can be shown by determining its binding to other receptors using standard assays, eg, one using a tritiated NKB derivative in a tissue preparation selective for NK3 receptors In general, the compounds of the invention that were tested showed statistically significant binding activity in Test A and Test B with a Kx of 1 mM or much smaller being measured in a typical way.

Rabbit Pulmonary Artery: In vitro Ki Functional Test (Test C) The ability of a compound of the invention to antagonize the action of the antagonist [Arg6, Sar9, Met (02) n] Substance P (6-11), ASMSP, in a lung tissue can be demonstrated as follows.

New Zealand white male rabbits were sacrificed by intravenous injection into the ear vein with 60 mg / kg of Nembutal (50 mg / mL). Preceding the Nembutal, Heparin was applied into the vein (1000 units / mL) at 0.0025 mL / kg for anticoagulation purposes. The thoracic cavity opens from the end of the costal arch to the sternum and the heart, lungs and part of the trachea are removed. The pulmonary arteries are isolated from the rest of the tissues and cut in half to serve as pairs. The segments are suspended between stainless steel stirrups, so that nothing is removed from the endothelium, and they are placed in water-filled tissue tubs (37 ° C) containing physiological saline of the following composition (mM): NaCl, 118.0; KCl, 4.7; CaCl2, 1.8; MgCl2, 0.54; NaH2P0, 1.0; NaHCO 3, 25.0 glucose, 11.0; indomethacin, 0.005 (to inhibit cyclooxygenase); and dl-Propanolol, 0.001 (to block β receptors); they are gasified continuously with 95% 02-5% C02. The answers are measured in a Grass polygraph via Grass FT-03 transducers. The initial tension placed on each fabric is 2 grams, which is maintained throughout the equilibrium period of 1.0 hour. The tissues are washed with physiological saline at 15 minute intervals. After 30 and 45 minutes of washing, the following treatments are added: 1 x 10-6 M of thiorphan (to block E.C.3.4.24.11), 3 x "M (S) -N- [2- (3,4-dichlorophenyl) -4- [4- (2-oxoperidropyrimidin-1-yl) piperidino] butyl] -N-methylbenzamide (to block NK2 receptors) , and the given concentration of the compound to be tested.At the end of 1.0 hour of equilibrium, 3 x 10"6 M of phenylephrine hydrochloride is added during 1.0 hour. At the end of 1.0 hour, a dose relaxation curve for ASMSP is formed. Each tissue is treated individually and is considered finished when it fails to relax after two additional consecutive doses. When a tissue is completed, a maximum of 1 x 10"3 M Papaverine is added for maximum relaxation.The percent inhibition is determined when a tested compound produces a statistically significant reduction (p <; 0.05) of total relaxation which is calculated using the total relaxation of Papaverine as 100%. The potencies of the compounds are determined by calculating the apparent dissociation constants (KB) for each concentration tested using the standard equation: KB = [antagonist] / (proportion of the dose - 1) where the proportion of the dose = antilog [(agonist-log molar EC50 without compound) - (-log molar ECso with compound)]. KB values can be converted to negative logarithms and expressed as -log molar KB (for example pKB). For this evaluation, the concentration-response curves for the agonist obtained in the absence and presence of the compound tested using paired pulmonary artery rings are completed. The agonist's potency is determined at 50% of its own maximum relaxation at each curve. The EC50 values are converted to negative logarithms and are expressed as -log molar ECso- NK2 functional assay in vitro (Test D) The ability of a compound of the invention to antagonize the action of the agonist [ß-ala8] NKA (4-10), BANK, in a lung tissue can be demonstrated as follows. New Zealand white male rabbits are sacrificed by intravenous injection into the vein of the ear with 60 mg / kg of Nembutal (50 mg / mL). Preceding Nembutal, Heparin was administered into the vein (1000 units / mL) at 0.0025 mL / kg for anticoagulation purposes. The thorax cavity opens from the end of the costal arch to the sternum and a small incision is made in the heart so that the left and right pulmonary arteries can be canalized with polyethylene tube PE260 and PE190 respectively). The pulmonary arteries are isolated from the rest of the tissues, then rubbed on an intimate surface to remove the endothelium, and cut in half to serve as pairs. The segments are suspended between stainless steel stirrups and placed in water-filled tissue tubs (37 ° C) containing physiological saline of the following composition (mM): NaCl, 118.0; KCl, 4.7; CaCl2, 1.8; MgCl2, 0.54; NaH2P0, 1.0; NaHCO 3, 25.0 glucose, 11.0; indomethacin, 0.005 (to inhibit cyclooxygenase); it is gasified continuously with 95% 02-5% C02. The answers are measured in a Grass polygraph via Grass FT-03 transducers. The initial tension placed on each fabric is 2 grams, which is maintained throughout the equilibrium period of 1.0 hour. The tissues are washed with physiological saline at 15 minute intervals. After the equilibrium period of 45 minutes, 3 x 10 ~ 2 M KCl is added for 60 minutes to test the viability of the tissues. The tissues are then washed extensively for 30 minutes. The concentration of the compound to be tested is then added over 30 minutes. At the end of 30 minutes, a cumulative dose response curve for BANK was performed. Each tissue is treated individually and is considered finished when it fails to contract after two additional consecutive doses. When a tissue is complete, 3 x 10"2 M BaClz is added for maximum concentration.The percent inhibition is determined when a tested compound produces a statistically significant reduction (p <0.05) of the total contraction which is calculated using the total contraction of BaCl2 as 100% The powers of the compounds were determined by calculating the apparent dissociation constants (KB) for each concentration tested using the standard equation: KB = [antagonist] / (proportion of the dose - 1) where the proportion of the dose = antilog [(agonist-log molar EC50 without compound) - (-log molar EC50 without compound)]. The KB values can be converted to negative logarithms and expressed as -log molar KB (by example pKB) For this evaluation, the concentration-response curves for the agonist obtained in the absence and presence of the compound tested using paired artery rings are completed. The power of the agonist is determined at 50% of its own maximum relaxation at each curve. The EC50 values are converted to negative logarithms and expressed as -log molar EC50.

Functional assay of NKi and NK2 in vivo (Test E) The activity of a compound as an antagonist of NKi and / or NK2 receptors can also be demonstrated in vivo in laboratory animals as described in: Buckner et al., 'Differential Blockade by Tachykinin NKi and NK2 Antagonist Receptor of Bronchoconstriction Induced by Direct -Acting Agonist and the Indirect-Acting Mimetics Capsaicin, Serotonin and 2-Methyl-Serotonin in the Anesthetized Guinea Pig. "J. Pharm. Exp. Ther., 1993, Vol 267 (3), pp. 1168-1175. The compounds are tested in anesthetized guinea pigs pretreated with intravenous indomethacin (10 mg / kg, 20 minutes), propranolol (0.5 mg / kg, 15 minutes), and thiorphan (10 mg / kg, 10 minutes). .

Antagonists or vehicles are administered intravenously and orally, 30 and 120 minutes prior to the increase of agonist concentrations, respectively. The agonists used in these studies are ASMSP (Ac- [Arg6, Sar9, Met (02) "j-SPtß-ll)) and BANK (ß-ala-8 NKA4-10). Administered intravenously, the ASMSP is selective for NKi receptors, and BANK is selective for NK2 receptors.The maximum response is defined as zero conductance (G L. 1 / Rp) .The ED50 values are calculated (the dose of agonist that results in a reduction of GL to 50% of the baseline), and converted to the negative logarithm (-logED50) .The ED50 values obtained in the presence (P) and absence (A) of antagonist, are used to calculate a Dose Ratio (P / A) , an expression of potency The data are expressed as mean + SEM and the statistical differences are determined using ANOVA / Tukey-Kramer and Student's t test, with p <0.05 considered statistically significant The compounds of the present invention exhibit activity marked in the preceding tests and are considered useful for the treatment of aq Those diseases in which the NKi and / or NK2 receptor is involved, for example, in the treatment of asthma and related conditions. The results of the testing of significant compounds of the present invention by the above methods are presented in Table I Table I Rabbit Pulmonary Artery Clinical studies Clinical studies to demonstrate the efficacy of a compound of the invention can be carried out using standard methods. For example, the ability of a compound to prevent or treat asthma symptoms or asthma-like conditions can be demonstrated using a challenge of cold air inhalation or allergen and evaluation by standard lung measurements, such as, for example, FEVi (forced expiratory volume in one second) and FVC (forced vital capacity), analyzed by standard methods of statistical analysis. It will be understood that the implications of the activity of the compounds in the Tests described above are not limited to asthma, but rather, that the Tests provide evidence of general antagonism of both SP and NKA. SP and NKA have been implicated in the pathologies of numerous diseases including: rheumatoid arthritis, Alzheimer's disease, cancer, schizophrenia, edema, allergic rhinitis, inflammation, pain, gastrointestinal hypermotility, aging, emesis, Huntington's disease, psychosis including depression , hypertension, migraine, hypermotility of the bladder and urticaria. Accordingly, a feature of the invention is the use of a compound of formula I or a pharmaceutically acceptable salt thereof in the treatment of a disease in a human or other mammal in need of those in which SP or NKA is involved and he wants the antagonism of his action. Asthma is characterized by chronic inflammation and hypersensitivity of the airways. The NKi receptor is known as a mediator of inflammation and hypersecretion of mucus in the airways; and the NK2 receptor is involved in the control of bronchial smooth muscle tone. Thus, agents capable of antagonizing the action of SP and NKA, and of the NKi and NK2 receptors, respectively, are capable of reducing both chronic inflammation and hypersensitivity of the airways that are symptomatic of asthma. It has been suggested that an antagonist having mixed affinity for the NKi and NK2 receptors could be therapeutically superior to a selective receptor antagonist. C.M. Maggi 'Tachykinin Receptors and Airway Pathophysiology "EUR, Respir J., 1993, 6, 735-742 to 739. Also, it has been suggested that a synergistic effect against bronchoconstriction may result from the simultaneous application of an NKi antagonist and one of NK2 DM Foulon, et al. * NK? and NK2 Receptors Mediated Tachykinin and Resiniferatoxin-induced Bronchospasm in Guinea Pigs "American Review of Respiratory Disease, 1993, 148, 915-921. Accordingly, another feature of the invention is the use of a compound of formula I or a pharmaceutically acceptable salt thereof in the treatment of asthma in a human or other animal in need thereof. There is a possible role for P antagonists in the treatment of depression. Accordingly, another feature of the invention is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of depression in a human or other mammal in need thereof.

Because of the range of effects attributable to the actions of SP and NKA, compounds that are able to block their actions may also be useful as tools to further evaluate the biological actions of other neurotransmitters in the tachykinin family. As a result, another feature of the invention is provided by the use of a compound of formula I or a salt thereof as a pharmacological standard for the development and standardization of new disease models or assays for use in the development of new agents. Therapeutics for the treatment of diseases in which SP or NKA are involved or for tests for their diagnosis.

EXAMPLES The invention will now be illustrated by the following non-limiting examples, in which, unless otherwise indicated: (i) the temperatures are given in degrees Celsius (° C); unless otherwise stated, the operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25 ° C; (ii) the organic solutions were dried over anhydrous magnesium sulfate; the evaporation of the solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascal, 4.5-30 mm Hg) with a bath temperature above 60 ° C; (iii) chromatography means silica gel spectrum chromatography; thin layer chromatography (TLC) was carried out on silica gel plates; (iv) in general, the course of reactions was followed by TLC and the reaction times are given only by way of illustration; (v) the melting points are uncorrected and (dec) indicates decomposition; (vi) the final products have satisfactory proton nuclear magnetic resonance (NMR) spectrum; (vii) when given, the NMR data are in the form of delta values for the highest proton diagnosis, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using chloroform deuterated (CDC13) as a solvent; conventional abbreviations are used for signal configuration; for the AB spectrum the changes observed directly are reported; the coupling constants (J) are given in Hz; Ar designates an aromatic proton when such an assignment is made; (viii) the reduced pressures are given as absolute pressures in Pascales (Pa); the high pressures are given as bar pressure gauge pressures; (ix) the percentages of solvent are given in terms of volume: volume (v / v); and (x) the mass spectra (MS) were run using an automated system with chemical ionization of atmospheric pressure (APCI). Generally, only the spectrum where the original masses are observed and represented. The lower bulk mass ion is reported for molecules where the splitting of the isotope results in multiple peaks of spectral mass (for example when chlorine is present). Terms and abbreviations: The solvent mixture compositions are given as percentages of volume or volume ratio. In cases where the NMR spectrum is complex, only diagnostic signals are reported, atm; atmospheric pressure, Boc; t-butoxycarbonyl, Cbz; benzyloxycarbonyl, DCM; methylene chloride, DIPEA: diisopropylethylamine, DMF; N, N-dimethylformamide, DMSO; dimethylsulfoxide, Et20; diethyl ether, EtOAc; ethyl acetate, h; hour (s), HPLC: high pressure liquid chromatography, min; minutes, NMR; nuclear magnetic resonance, psi; pounds per square inch; TFA; trifluoroacetic acid, THF; tetrahydrofuran. Standard reductive amination refers to the typical procedure in which a solution of an amine (1-1.2 equivalents), an aldehyde (1-1.2 equivalents) and acetic acid (2 equivalents) are stirred in methanol for 5 to 60 min before the addition of NaBH3CN (1.7 equivalents). After 1-16 h the reaction is optionally concentrated, dissolved in DCM, and washed with saturated sodium bicarbonate and then purified by chromatography. The standard Swern oxidation conditions refer to the oxidation of an alcohol to the corresponding aldehyde in accordance with Mancuso, AJ; Huang, SL; Swern, D; J. Org. Chem .; 1978, 2840. The standard formation of an acid chloride refers to the typical procedure in which a solution of a naphthoic acid or substituted naphthoic acid in DCM is mixed with 1-1.2 equivalents of oxalyl chloride and a catalytic amount of DMF for 1 -12 h, concentrated under reduced pressure, and used without purification. Standard acylation refers to the typical procedure in which an acid chloride (1-1.2 equivalents) is added to a mixed solution of an amine (1-1.2 equivalents) and triethylamine (2 equivalents) in DCM.

After 1-16 h the reaction is optionally concentrated, dissolved in DCM, and washed with saturated sodium bicarbonate and then purified by chromatography. Where it was noted that a final compound was converted to the citrate salt, the free base was combined with citric acid (1.0 equivalent) in methanol, concentrated under reduced pressure and dried under vacuum (25-70 ° C). When it was indicated that a compound was isolated by Et20 filtration, the citrate salt of the compound was mixed for 12-18 h, removed by filtration, washed with Et20, and dried under vacuum at 25-70 ° C. Where it was noted that a final compound was converted to the hydrochloride salt, a solution of HCl in Et20 was added, with stirring to a solution of the purified free base in DCM or methanol. The resulting precipitate was collected by filtration and dried in vacuo. Each compound bearing a 2-substituted naphthamide was presented as a mixture of conformational isomers (atropisomers); it is believed that this results from the slow rotation around the amide and / or aryl bonds. Such compounds showed multiple peaks in the HPLC chromatograms and highly complex NMR spectrum. In some cases, the individual components of an atropiomeric mixture could be purified by reverse phase HPLC and the properties could be evaluated independently.

EXAMPLE 1 N- [(S) -2- (3,4-Dichlorophenyl) -4- [4- [(S) -2- ethylsulfinylphenyl] -1-piperidinyl] util] -N-methyl-2-methoxy citrate -3-cyano-1-naphtamide.

A solution of 2-methoxy-3-cyano-l-naphthoic acid (0.065 g), oxalyl chloride (0.039 g) and DMF (about 5 mL) was stirred for 1.5 h then concentrated to provide 2-methoxy-3-chloride. -cyano-l-naphthoyl as a white residue that was used directly. Using standard acylation conditions the 2-methoxy-3-cyano-l-naphthoyl chloride was reacted (0.065 g) with N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-amine ( 0.136 g). The free base (0.170 g) was converted to the citrate salt. ? NMR (DMSO-d6): d 8.71-8.63 (m, 1H), 8.08-8.00 (m, 1H) 7.85-7.33 (m, 8.68, 1H), 7.11-6.85 (m, 0.6H), 6.31-6.28 ( m, 0.47, 1H), 4.57-0.96 (m, 22H); MS m / z 662 (M + H). The required 2-methoxy-3-cyano-l-naphthoic acid was prepared as follows. (a) 3-Hydroxy-4-iodo-2-naphthoic acid A mixture of NaOH (2.12 g) in methanol (100 mL) was stirred until the solution was homogeneous. Sodium iodide (3.98 g) and 3-hydroxy-2-naphthoic acid (5.00 g) were added and stirred for 30 minutes. The resulting suspension was cooled to 0 ° C and an aqueous solution of sodium hypochlorite at 5.25% (w / v) was added dropwise and the mixture was continued for 1 h. Saturated sodium thiosulfite (25 mL) was added and after 5 minutes the solution was acidified to a pH of 2 by the addition of 6 N of HCl resulting in the formation of a yellow precipitate which was filtered and washed with water (50 ml). mL). The precipitate was transferred to a round bottom flask, dissolved in methanol (70 mL) and toluene (100 mL), concentrated, redissolved in methanol (70 L) and toluene (100 L) and concentrated to provide the product as a yellow solid (6.26 g). MS m / z 313 (M-1). XH NMR (DMSO-de): d 12.41 (broad, 1H), 8.63 (s, 1H) 8.05-7.97 (m, 2H), 7.70 (m, 1H), 7.42 (m, 1H). (b) Methyl 3-methoxy-4-iodo-2-naphthoate. A solution of 3-hydroxy-4-iodo-2-naphthoic acid (8.0 g), dimethyl sulfate (8.03 g), potassium carbonate powder (8.80 g) and dry acetone (150 mL) was heated under reflux for 18 hours . The solution was cooled to room temperature, triethylamine (15 mL) was added, and stirring was continued for 30 min. The solution was filtered through a pad of Celite and washed with dry acetone (50 mL). The filtrate was concentrated to a yellow oil, diluted with EtOAc, and washed successively with 1N HCl (100 mL), saturated aqueous sodium bicarbonate (100 mL), and saline (100 mL). The organic phase was dried (sodium sulfate), filtered, concentrated, and purified by chromatography (0-10% ETOAc in hexanes) to give the product as a yellow oil (5.53 g 1H NMR (DMSO-d6) : d 8.47 (s, 1H), 8.09 (m, 2H), 7.74 (m, 1H), 7.61 (m, 1H), 3.94 (s, 3H), 3.87 (s, 3H). (c) l-iodo-2-methoxy-3-cyanonaphthalene. Based on the procedure of Wood, JL; Khatri, NA; Weinreb, SM; Tetrahedron Lett; 51, 4907 (1979), methyl 3-methoxy-4-iodo-2-naphthoate (5.0 g) was suspended in xylenes (100 mL), cooled to 0 ° C, dimethylaluminum amide solution (approximately 37 mmol) was added and the solution was heated under reflux for 2.5 h. The solution was then cooled to 0 ° C and acidified to a pH of 2 by the addition of IN of HCl and extracted with ETOAc (3 x 100 mL).

The combined EtOAc extracts were washed with saturated aqueous sodium bicarbonate (150 mL) and saline (150 mL), dried (sodium sulfate), filtered, concentrated, and purified by chromatography. (1: 1 EtOAc: DCM, then 10% 20% ETOAc in DCM) to give the product as a white solid (3.29 g). XH NMR (DMSO-dβ): d 8.69 (s, 1H), 8.24-8.04 (m, 2H), 7.91-7.81 (m, 1H), 7.76-7.75 (m, 1H), 3.99 (s, 3H); MS m / z 311 (M + H). (d) Methyl 2-methoxy-3-cyano-l-naphthoate. Through a suspension of l-iodo-2-methoxy-3-cyanonaphthalene (0.250 g), Pd (Oac) 2 (0.018 g), triethylamine, (0.081 g) and methanol (20 mL) was made to boil carbon monoxide for 25 minutes, then stirred at 70 ° C under carbon monoxide (1 atm) for 18 hours. The solution was cooled, filtered, rinsed with methanol (20 mL) and DCM (20 mL), concentrated, preabsorbed in silica (1 g) and purified by chromatography (0-10% EtOAc in hexanes) to provide the product as a white solid (0.113 g). XH NMR (DMSO-de): d 8.78 (s, 1H), 8.12-8.09 (m, 1H), 7.84-7.78 (, 2H), 7.70-7.63 (m, 1H), 4.02-4.01 (m, 6H); IR (cm "1): 2228, 1724, 1296, 1236, 1208, 1017. (e) 2-methoxy-3-cyano-l-naphthoic acid A solution of methyl 2-methoxy-3-cyano-l-naphthoate (0.113 g) and LiOH-H20 (0.0196 g) THF (3 L), water (1 mL) and methanol (1 mL) was stirred overnight at room temperature, the solution was diluted with saturated sodium bicarbonate and extracted with Et20. The aqueous layer was acidified to a pH of 2 by the addition of IN of HCl and extracted with Et20. The organic layer was washed with water (30 mL) and saline (40 mL), dried (sodium sulfate), filtered, and concentrated to a white solid. 1 H NMR (DMSO-dβ): d 14.06 (broad, 1H), 8.08-8.02 (m, 1H), 7.83-7.76 (m, 2H), 7.69-7.63 (m, 1H), 4.02 (s, 3H); MS m / z: 226 (M-1). The required N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1- piperidinyl] butyl] -N-methylamine was prepared as follows. (f) N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-N-Boc amine. (S) -N- [2- (3,4-Dichlorophenyl-4-oxobutyl] -N-methyl-N-Boc-amine (Miller, SC, WO 9505377) (51.7 g, 149.3 mmol), 4- [ (S) -2-methylsulfinylphenyl] -piperidine (Shenvi, AB; Jacobs, RT; Miller, SC; Ohnmacht, CJ, Jr .; See it, CA. , WO 9516682) (36.7 g, 164.3 mmol), and glacial acetic acid (9.9 g, 165.0 mmol) were dissolved in methanol (1000 L), and the solution was stirred for 15 minutes. Sodium cyanoborohydride (10.4 g, 165.5 i-imol) was added in portions as a solid for 30 minutes. The mixture was stirred for 20 hours, then treated with saturated sodium bicarbonate (500 mL). The methanol was removed in vacuo, and the aqueous residue was extracted with DCM (4x400 mL). The organic layer was washed with saline (300 mL), dried (MgSO), filtered, and concentrated in vacuo. The residue was purified by chromatography (0-6% methanol in DCM) to give a white foam (77.2 g, 93% MS: 553 (M + H). XH NMR (CDCl3): d 1.40 (s, 9H, t -C4H9), 1.61-2.04 (m, 9H, CH), 2.14-2.23 (m, 2H, CH), 2.62-2.79 (m, 6H, NCH3, SOCH3), 2.91-3.00 (m, 3H, CH); 3.27-3.54 (m, 2H, CH); 7.00-7.09 (m, 1H, aromatic); 7.21-7.53 (m, 5H, aromatic); 7.95-8.04 (m, 1H, aromatic). (G) N- [ (S) -2- (3,4-Dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine The N- [(S) -2- (3 , 4-Dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine-N-Boc-amine (77.0 g, 139.0 mmol) was dissolved in DCM (1200 mL). To the stirred solution was added trifluoroacetic acid (160.0 g, 1.40 mol) by dripping for 15 minutes. The mixture was stirred for 4 hours, then additional trifluoroacetic acid (80.0 g, 0.70 mol) was added, and the mixture was stirred for an additional 1.5 hours. The mixture was washed with aqueous sodium carbonate (225 g, 1500 mL of water), water (2x500 L), then dried (MgSO4). Filtration and concentration led to the crude product as a yellow gum. Purification by chromatography (0-20% methanol / DCM) gave a light yellow foam (61.8 g, 98%). MS: 453 (M + H). XH NMR (CDCl 3): d 1.64-2.09 (, 7H, CH); 2.27-2.35 (m, 2H, CH); 2.46 (s, 3H, NCH3); 2.68 (s, 3H, S0CH3); 2.74-3.05 (m, 7H, CH); 3.39-3.78 (bs, 1H, NH); 7.07-7.10 (m, 1H, aromatic); 7.23-7.50 (m, 5H, aromatic); 7.95-7.99 (m, 1H, aromatic).

Example 2 N- [(S) -2- (3, -Dichlorophenyl) -4- [4- [(S) -2-ylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-2, 3-citrate -dimethoxy-1-naphtamide Using standard acylation conditions the N - [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine was made react with 2,3-dimethoxy-1-naphthoyl chloride and converted to the citrate salt. MS m / z 667 (M + H); Analysis for C36 H0Cl2N2O4S »1.0 C6H80 1.2 H20; calculated: C, 57.23; H, 5.76; N, 3.14; found: C, 57.22; H, 5.76; N, 3.18. The required carboxylic acid was prepared as follows. (a) 2, 3-Dihydroxy-1-naphthaldehyde.

A stream of HCl gas was passed through a mixture of 2,3-dihydroxynaphthalene (6.0 g, 37.4 mmol) and zinc cyanide (6.6 g, 56.1 mmol) in dry ether (28 mL) at 0 ° C during 20 minutes, producing an insoluble yellow oil. Stirring was continued for 1 hour at 0 ° C, then at room temperature for 1 hour. The brown yellow oil was separated and washed with ether. Water (120 mL) was added and the mixture was heated at 60 ° C for 10 minutes. The yellow solid generated was filtered and washed with water to yield the title product (5.48 g, containing 20% of the initiator material MS m / z 187 (M-H). (b) 2, 3-dimethoxy-1-naphthaldehyde A mixture of 2,3-dihydroxyl-1-naphthaldehyde (4.87 g, 25.8 ml-ol), potassium carbonate (14.2 g, 102.9 mmol), and CH 3 I ( 16 mL, 258 mmol) in acetone (80 mL) at 59 ° C for 29 hours. The solvent was evaporated and the mixture was diluted with ETOAc. The organic layer was dried (MgSO 4), filtered, and concentrated. Following purification by chromatography the product was recovered as white solid (3.7 g, 66%). X H NMR (CDCl 3): d 10.82 (s, 1 H), 9.10 (d, 1 H), 7. 71 (d, 1H), 7.51 (m, 2H), 7.43 (s, 1H), 4.06 (s, 3H), 4.03 (s, 3H). MS m / z 217 (M + H). (c) 2,3-dimethoxy-1-naphthoic acid To a solution of 2,3-dimethoxy-1-naphthaldehyde (3.7 g, 17.1 mmol) in acetone was added sodium carbonate (1.81 g, 17.1 mmol) in water (9 mL). Potassium permanganate (2.7 g, 17.1 mmol) was added in portions. The solution was stirred at room temperature for 3 hours and filtered. The filtrate was concentrated and extracted with ETOAc. The aqueous layer was acidified to a pH of 1 by the addition of IN of HCl, then extracted with ETOAc. The combined organic layers were dried (MgSO4), filtered and concentrated to give the product as a yellow solid (2.41 g, 61%). XH NMR (DMSO): d 13.46 (s, 1H), 7.86 (d, 1H), 7.63 (d, 1H), 7.51 (s, 2H), 7.42 (m, 2H), 3.96 (s, 3H), 3.83 (s, 3H). MS m / z 231 (M-H).

EXAMPLE 3 N- [(S) -2- (3,4-Dichlorophenyl) -4- [4- [(S) -2-methylsulfinyl-enyl] -1-piperidinyl] butyl] -N-methyl- citrate hydrate 2-ethoxy-1-naph amide.

To a stirred solution of 2-ethoxy-l-naphthoic acid (106.5 mg, 0.492 mmol) in dry DCM (2 mL) was added oxalyl chloride (75.7 mg, 0.596 mmol) and DMF (5 DL). After 3 hours at room temperature in DCM it was removed in vacuo to give 2-ethoxy-1-naphthoyl chloride. Using standard acylation conditions (with the exception that the order of the addition was the reverse), 2-ethoxy-1-naphthoyl chloride was reacted with N - [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine (203 mg, 0.448 mmol), was converted to citrate salt and isolated by filtration of ET20 to provide the compound of the title (301.3 mg) as a white powder. MS m / z 651 (M + H); Analysis for C3e H4oCl2N2? 3S "C6H8? 7 'H20; calculated: C, 58. 53; H, 5.85; N, 3.25; found: C, 58.70; H, 5. 65; N, 3. 17.

EXAMPLE 4 N- [(S) -2- (3,4-Dichlorophenyl) -4- [4- [(S) -2-methylsul inyl] -1-piperidinyl] util] -N-methyl-2 citrate -methoxy-1-naphtamide.

In accordance with the procedure described in Example 1, 1,2-methoxy-1-naphthoic acid (0.071 g) was converted to acid chloride; 2-methoxy-l-naphthoyl chloride. Using standard acylation conditions the N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methy1-sulfinylphenyl] -1-piperidinyl] butyl] -N- was reacted methylamine (0.238 g) with 2-methoxy-1-naphthoyl chloride. The free base (0.149 g) was converted to the citrate salt. MS m / z: 637 (M + H).

Example 5 N- [(S) -2- (3, -Dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -l-piperidinyl] butyl] -N-methyl-2-methyl- citrate l-naphtamide.

In accordance with the procedure described in Example 1, 2-methyl-1-naphthoic acid (0.100 g) was converted to acid chloride and reacted with N- [(S) -2- (3,4-dichlorophenyl) - 4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine (0.2435 g) using standard acylation conditions. The free base (0.255 g) was converted to the citrate salt. MS m / z 621 (M + H).

Example 6 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-2-chloro citrate -l-naftamide.

Under standard conditions, 2-chloro-1-naphthoyl chloride was prepared from 2-chloro-1-naphthoic acid (Chatterjea, JN; et al; J. Indian Chem. Soc., 35, 41, (1958)) using oxalyl chloride. This material (0.10 g) was reacted with N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -l-piperidinyl] butyl] -N -methylamine (0.219 g) using standard acylation conditions. The free basic product (0.174 g) was converted to the citrate salt. MS m / z 641 (M + H).

Example 7 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [4-methoxy- (S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl citrate -3-cyano-2-methoxy-1-naphtamide.

Using standard reductive amination conditions N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-N-methyl-3-cyano-2-methoxy-1-naphthamide (0.939 g) was made react with 4- [4-methoxy- (S) -2-methylsulfinylphenyl] -piperidine (0.525 g) and converted to the citrate salt. MS: m / z 692 (M +); 1H NMR (DMSO-dβ) d 8.75-8.60 (m), 8.20-6.70 (m), 6.31 (d), 4.54 (t), 4.10-3.65 (m), 3.60-3.00 (), 2.90-2.30 (m), 2.20-1.60 (m); Analysis for C37H39Cl2N3? 4S-1. 0 citric acid - 1.5 H2O »0. 50 Et20: calculated; C, 56. 96; H, 5. 84; N, 4.43; found; C, 56.78; H, 5.52; N, 4.39. The required [4-methoxy- (S) -2-methylsulfinylphenyl] -piperidine was prepared as follows.

Ski (a) 2-Bromo-5-methoxyphenol (2). To a solution of 3-methoxyphenol (129.03 g) and benzoyl peroxide (1.00 g) in 500 L of 1,1,1-trichloroethane (TCE) was slowly added a solution of bromine (167.90 g in 150 mL in 1, 1,1-TCE) during Ih. During the addition, the reaction flask was irradiated with a GE ultraviolet lamp (275 watt, 120 volt) which caused a gentle reflux to occur. The released HBr was captured in a precipitation bucket containing a solution of 126.02 g of NaHCO3 and 800 mL of water. When the bromine addition was complete the reaction mixture was purged with nitrogen for 20 min. The reaction mixture was extracted with saturated NaHCOß until the pH of the aqueous extract was neutral. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a reddish oil. The crude product was purified by vacuum distillation (150 ° C, 150 millitor) to give 161.78 g of a viscous liquid; XH NMR (CDC13) d 3.77 (s, 3), 5.57 (s, 1), 6.42 (m, 1), 6.60 (d, 1), 7.30 (d, 1). (b) 2-Bromo-5-methoxy- (N, N-dimethylthiocarbamoyloxy) phenol (3). To a stirred solution of 2-bromo-5-methoxyphenol (161.78 g) and 1,4-diazabicyclo [2.2.2] octane (180.03 g) in 1 L of DMF was added slowly 200 g of dimethylthiocarbamoyl chloride in four portions of 50 g separated for 30 min. When the addition was complete the mixture was stirred overnight (18 h) under a nitrogen atmosphere. At the end of this period the mixture was emptied into 4 L of distilled water with rapid stirring. The precipitated product was collected by filtration and washed with water. The crude product was air dried for 4 h and crystallized from methanol to give white crystals (139.19 g); 1 H NMR (300 MHz, CDC13) d 3.38 (s, 3), 3.47 (s, 3), 3.79 (s, 3), 6.71 (m, 2), 7.45 (m, 1); MS: m / z 290 (M + H). (c) 4-Bromo-3- (N, N-dimethylcarbamoylthio) methoxybenzene (4).

A solution of 2-bromo-5-methoxy- (N, N-dimethylthiocarbamoyloxy) phenol (139.19 g) and N, N-diethylaniline (350 mL) (4 cycles) and then heated under reflux under nitrogen for 3.5 h. The resulting brown solution was concentrated (short-path distillation) to about 100 mL and the residue was emptied into 500 mL of 6N HCl as ice-cooled with rapid stirring. The mixture was cooled to room temperature, 100 mL of Et20 was added, and a heavy precipitate formed which was collected by filtration. This brown precipitate (crude product) was briefly air-dried and placed on the side. The filtrate was extracted with Et20. The Et20 extracts were combined, dried over MgSO4, filtered, and concentrated under reduced pressure to give a brownish solid (additional crude product). The crude product was purified by crystallization of methanol to give off white crystals (82.04 g). 1 H NMR (300 MHz, CDC13) d 3.05 (br s, 3), 3.12 (br s, 3), 3.79 (s, 3), 6.82 (dd, 1), 7.19 (d, 1), 7.55 (d, 1); MS: 290 (M + H). (d) 4-Bromo-3- (methylthio) -methoxybenzene (5). To a stirred solution of KOH (120.01 g) in 500 mL of methanol was added 82.04 g of 4-bromo-3- (N, N-dimethylcarbamoylthio) methoxybenzene. The mixture was refluxed under a nitrogen atmosphere for 2 h, then cooled to 0 ° C and neutralized with 400 mL of 6N HCl. The mixture was cooled to 0 ° C and extracted with DCM. The organic extracts were combined, dried over Na 2 SO 4, filtered, and concentrated under reduced pressure to give a clear brown liquid. This liquid was dissolved in 600 mL of anhydrous DMF and treated with 80.90 g of anhydrous K2CO3. The resulting mixture was stirred for 20 min and then 68.40 g of methyl iodide was slowly added over 15 min. The resulting mixture was stirred at room temperature under nitrogen atmosphere overnight (18 h). At the end of this period the reaction mixture was emptied into 2.8 L of distilled water and extracted with Et20. The organic layers were combined, dried over MgSO4, filtered, and concentrated under reduced pressure to give a pale yellow liquid (65.03 g). XH NMR (CDC13) d 2.45 (s, 3), 3.80 (s, 3), 6.55 (dd, 1), 6.66 (d, 1), 7.39 (d, 1). (e) 4-Hydroxy-4- (4-methoxy-2-methylthiophenyl) -N-Cbz-piperidine (7). The cerium (III) chloride heptahydrate (181.38 g) was heated under a high vacuum at 100 ° C for 2 days thereafter at 140 ° C for two days. This material was transferred to a dry flask equipped with a mechanical stirrer, suspended in 700 mL of anhydrous THF, and stirred while cooling to -78 ° C. A solution of 4-bromo-2- (methylthio) methoxybenzene in 500 mL of anhydrous THF was cooled to -78 ° C and treated dropwise with n-butylithium (111.5 mL of a 2.5 M solution in hexane) for 1 hour. The temperature of the reaction flask was maintained below -70 ° C during the addition. This mixture was stirred at -78 ° C for 1.5 hours and transferred via a high-caliber isolated cannula into the flask containing the stirred suspension of CeCl3 at -78 ° C. The resulting peach-colored suspension was stirred for 1.5 h at -78 ° C and then a solution of 1-benzyloxycarbonyl-4-piperidone (65.10 g in 200 mL of anhydrous THF) was added via a cannula for 30 minutes. When the addition was complete the reaction mixture was warmed to room temperature and stirred overnight (18 h). At the end of this period the reaction mixture was quenched with 500 mL of saturated NH 4 Cl and stirred for 30 minutes. The organic layer was decanted, concentrated under reduced pressure, and set aside. The remaining grayish suspension was stirred with 1 L of DCM and filtered through Celite. The Celite filter pad was washed with DCM. All organic extracts were combined, dried over Na 2 SO 4, filtered, and concentrated under reduced pressure to give a viscous oil which was purified by silica chromatography (1: 1, EtOAc: hexane) to give 85.00 g of an oil . XH NMR (CDC13) d 1.99 (m, 2), 2.12 (m, 2), 2.52 (s, 3), 3.39 (m, 2), 3.81 (s, 3), 4.10 (m, 3), 5.15 (s, 2), 6.71 (dd, 1), 6.95 ( d, 1), 7.24 (d, 1), 7.37 (m, 5); MS: 387 (M + H). (f) 4- (4-Methoxy-2-methylthiophenyl) -N-Cbz-piperidine (8). To a stirred paste rapidly cooled with ice of 4-hydroxy-4- (4-methoxy-2- (methylthio) -phenyl) -N-Cbz-piperidine (50.09 g) in triethylsilane (29.12 g) was slowly added acid trifluoroacetic (29.60 g). When the addition was complete the mixture was warmed to room temperature and stirred overnight (18 h). At the end of this period the mixture was emptied into 300 mL of saturated NaHCO 3 and extracted with DCM. The extracts were combined, dried over Na 2 SO 4, filtered, and concentrated under reduced pressure to give an oil. The product was purified by chromatography on silica (gradient 40: 1 to 20: 1, DCM: EtOAc) to give 42.50 g of an oil. ? E NMR (CDC13) d 1.57 (m, 2), 1.83 (d, 2), 2.46 (s, 3), 2.91 (m, 2), 3.06 (tt, 1), 3.80 (s, 3), 4.33 (m, 2), 5.14 (s, 2), 6.68 (dd, 1), 6.76 (d, 1), 7.04 (d, 1), 7.36 (m, 5); MS: m / z 394 (M + Na). (g) 4- (4-Methoxy-2- (S) -methylsulfinylphenyl) -N-Cbz-piperidine (9). To a 500 mL flask was added 11.56 g of diethyl-D-tartrate, 140 mL of anhydrous DCM, 7.96 g of titanium (IV) isopropoxide, and 0.50 g of water. The pale yellow solution was stirred for 30 minutes and then treated with 10.78 g of 4- (4-methoxy-2-methylthiophenyl) -N-Cbz-piperidine dissolved in 40 mL of DCM. The reaction mixture was then immersed in a water / glycol bath previously cooled to -30 ° C. After stirring for 30 min (bath temperature -36 ° C), 5.6 mL of a 6M solution of tert-butylhydroperoxide in nonane was slowly added to the reaction mixture and stirred for 6 days under nitrogen atmosphere ( -38 ° C bath). At the end of this period the reaction was stopped with 50 mL of water and stirred vigorously for 1 hour while heating to room temperature. The mixture was then treated with 100 mL of 2.5 M NaOH and stirred for a further 20 min, filtered through Celite and the layers were separated. The filter pad was washed with DCM twice and each portion was used to extract the aqueous layer. The organic extracts were combined, dried over Na 2 SO 4, filtered, and concentrated under reduced pressure. This gave a light yellow oil which was purified by chromatography on silica (4: 1, EtOAc: DCM). XH NMR (CDC13) d 1.62 (m, 2), 1.79 (m, 2), 2.86 (m, 3), 2.87 (s, 3), 4.34 (m, 2), 5.16 (s, 2), 7.00 ( dd, 1), 7.18 (d, 1), 7.36 (m, 5), 7.52 (d, 1); MS: m / z 410 (m + Na). (h) 4- (4-Methoxy-2- (S) -methylsulfinylphenyl) piperidine (10). To a solution of KOH (1.50 g) in 20 mL of 1: 1 EtOH: water was added 1.23 g of 4- (4-methoxy-2- (S) -methylsulfinylphenyl) -N-Cbz-piperidine. The resulting mixture was heated under reflux under a nitrogen atmosphere for 18 h, evaporated, dissolved in 10 mL of water, and extracted with CHCl3. The organic extracts were combined, dried over Na 2 SO 4, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica chromatography (19: 1, DCM: MeOH with 0.5% aqueous NH 4 OH) to give 0.38 g of white solid. XH NMR (CDC13) d 1.69 (m, 2), 1.82 (m, 2), 2.38 (m, 1), 2.70 (s, 3), 2.75 (m, 2), 3.22 (m, 2), 3.88 ( s, 3), 7.01 (dd, 1), 7.28 (d, 1), 7.51 (d, 1); MS: 254 (M + H). (i) N- [2- (S) - (3,4-Dichlorophenyl) -4-oxobutyl] -N-methyl-3-cyano-2-methoxy-1-naphtamide. N- [(S) -2- (3,4-dichlorophenyl) -4-hydroxybutyl] amine (Miller, SC, WO 9512577) was reacted with 3-cyano-2-methoxy-1-naphthoic acid using Schotten conditions Baumann to achieve N- [2- (S) - (3,4-dichlorophenyl) -4-hydroxybutyl] -N-methyl-3-cyano-2-methoxy-1-naphthamide [1H NMR (300 MHz, DMSO-de) d 9.70-9.64 (m), 8.67-8.57 (m), 8.07-7.97 (m), 7.80 (s), 7.72-7.55 (m), 7.52-7.48 (m), 7.40-7.33 (m), 7.12-7.10 (d), 7.04-7.02 (d), 6.87-6.83 (m) , 6.37-6.29 (d), 4. 53-4.44 (t), 4.11-4.00 (m), 3.94 (s), 3.92 (s), 3.91-3.73 (), 3.71 (s), 3.45-3.38 (m), 3.33 (s), 3.14 (s), 2.97-2.95 (d), 2.63 (s), 2.60 (s); MS APCI, m / z = 455 (M +)]. The alcohol was oxidized using oxalyl chloride and DMSO under standard Swern conditions to achieve the aldehyde N- [2- (S) - (3,4-dichlorophenyl) -4-oxobutyl] -N-methyl-3-cyano-2 -methoxy-1-naphthamide [XH NMR (300 MHz, DMSO-d6) d 9.70-9.64 (m), 8. 67-8.57 (m), 8.07-7.97 (m), 7.80 (s), 7.72-7.55 (m), 7.52- 7.48 (m), 7.40-7.33 (m), 7.12-7.10 (d), 7.04-7.02 (d), 6.87-6.83 (m), 6.37-6.29 (d), 4.53-4.44 (t), 4.11-4.00 (m), 3.94 (s), 3.92 (s), 3.91-3.73 (m), 3.71 (s), 3.45-3.38 (m), 3.33 (s), 3.14 (s), 2.97-2.95 (d), 2.63 (s), 2.60 (s); MS APCI, m / z = 455 (M +)].

Example 8 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-2-ethoxy citrate -3-cyano-1-naphthamid.

A solution of 2-ethoxy-3-cyano-l-naphthoic acid (0.106 g), oxalyl chloride (0.067 g) and DMF (about 5 DL) was stirred for 1.5 h then concentrated to achieve 2-ethoxy chloride -3-cyano-l-naphthoyl as a white residue which was used directly. Using standard acylation conditions the 2-ethoxy-3-cyano-1-naphthoyl chloride (0.114 g) was reacted with N - [(S) -2- (3,4-dichlorophenyl) -4- [4- [ (S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine (0.220 g) to give the free base (0.264 g) which was converted to the citrate salt: XH NMR (300 MHz, CDC13) d 8.70-8.62 (m), 8.08-6.25 (m), 4.64-4.56 (m), 4.23-3.91 (m), 3.17-1.79 (m), 1.37-1.32 (t, -CH3), 1.24-1.17 ( t, -CH3); MS APCI, m / z = 676 (M +). The required 2-ethoxy-3-cyano-l-naphthoic acid was prepared as follows. (a) Ethyl 3-ethoxy-4-iodo-2-naphthoate. A solution of 3-hydroxy-4-iodo-2-naphthoic acid (2.0 g), diethyl sulfate (2.94 g), potassium carbonate powder (3.52 g), and dry acetone (150 mL) was heated under reflux for 18 hours. h. The solution was cooled to room temperature, triethylamine (5 mL) was added, and stirring was continued for 30 min. The solution was filtered through a pad of Celite and washed with dry acetone (50 mL). The filtrate was concentrated to a yellow oil, diluted with EtOAc, and washed successfully with IN HCl (100 mL), saturated aqueous sodium bicarbonate (100 mL), and saline (100 mL). The organic phase was dried (sodium sulfate), filtered, concentrated, and purified by chromatography (0-10% EtOAc in hexanes) to give the product as a yellow oil (2.29 g). 1 H NMR (300 MHz, DMSO-dβ) d 8.43 (s, 1 H), 8.09 (m, 2 H), 7.75 (, 1 H), 7.62 (m, 1 H), 4.35 (m), 4.04 (q), 1.39 ( m); MS APCI, m / z = 393 (M + Na). (b) l-Iodo-2-ethoxy-3-cyanonaphthalene. Based on the procedure of Wood, JL; Khatri, NA; Weinreb, SM; Tetrahedron Lett; 51, 4907 (1979), ethyl 3-ethoxy-4-iodo-2-naphthoate (2.29 g) was suspended in xylenes (100 mL), cooled to 0 ° C, dimethylaluminum amide solution (approximately 15.4 mmol ) and the solution was heated under reflux for 2.5 h. The solution was then cooled to 0 ° C and acidified to pH 2 by the addition of 1N HCl and extracted with EtOAc (3 x 100 mL). The combined EtOAc extracts were washed with saturated aqueous sodium bicarbonate (150 mL) and saline (150 mL), dried (sodium sulfate), filtered, concentrated, and purified by chromatography (1: 1 EtOAc DCM, then 10-20% EtOAc in DCM) to provide the product as a white solid (0.778 g). XH NMR (300 MHz, DMSO-d6) d 8.68 (s, 1H), 8.25 (d, 1H), 8.13 (d, 1H), 7.86 (dd, 1H), 7.70 (dd, 1H), 4.21 (q, 2H), 1.50 (t, 3H). (c) Methyl 2-ethoxy-3-cyano-l-naphthoate. Through a suspension of l-iodo-2-ethoxy-3-cyanonaphthalene (0.650 g), Pd (0ac) 2 (0.045 g), triethylamine (0.305 g) and methanol (30 mL) was bubbled with carbon monoxide for 25 min, then stirred at 70 ° C under carbon monoxide (1 atm) for 18 h. The cooled solution was filtered, rinsed with methanol (20 mL) and DCM (20 mL), concentrated, preabsorbed in silica (3 g) and purified by chromatography (0-10% EtOAc in hexanes) to provide the product as a white solid (0.252 g). -? NMR (300 MHz, DMSO-d6) d 8.78 (s, 1H), 8.11 (d, 1H), 7. 77 (, 2H), 7.66 (m, 1H), 4.23 (q, 2H), 4.01 (s, 3H), 1.37 (t, 3H). (d) 2-Ethoxy-3-cyano-l-naphthoic acid. A solution of methyl 2-ethoxy-3-cyano-l-naphthoate (0.252 g) and LiOH (0.024 g), THF (5 mL), water (2 mL) and methanol (2 mL) was stirred overnight at room temperature. ambient. The solution was diluted with saturated sodium bicarbonate and extracted with Et20. The aqueous layer was acidified to pH 2 by the addition of IN HCl and extracted with Et20. The organic layer was washed with water (30 mL) and saline (40 L), dried (sodium sulfate), filtered, and concentrated to a white solid (0.141 g). ^ NMR (300 MHz, DMSO-d6) d 14.00 (b, 1H), 8.72 (s, 1H), 8.09 (d, 1H), 7.81 (m, 2H), 7.64 (m, 1H), 4.25 (q, 2H), 1.32 (t, 3H).

Example 9 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [2-methylsulfonylphenyl] -1-piperidinyl] butyl] -N-methyl-2-methoxy-3-cyano citrate -1-naphtamide. 4- (2-Methylsulfonylphenyl) piperidine (Shenvi, AB; Jacobs, RT; Miller, SC; Ohnmacht, CA; Veale, CA. WO 9516682) was reacted with N- [2- (S) - (3, 4 -dichlorophenyl) -4-oxobutyl] -N-methyl-3-cyano-2-methoxy-1-naphtamide according to the standard reductive amination methodology to give the free base which was converted to the title compound. 1 H NMR (300 MHz, DMSO-de) d 8.74-8.64 (m), 8.08-7.98 (), 7.94-7.90 (m), 7.81-7.70 (m), 7.67-7.48 (m), 7.39-7.34 (t ), 7.10-7.05 (m), 6.90-6.83 (m), 6.31-6.28 (d), 4.59-4.51 (t), 4.04 (s), 4.01 (s), 3.95 (s), 3.96 (s), 3.89-3.65 (m), 3.27 (s), 3.23-3.08 (m), 2.72-2.57 (m), 2.44-2.07 (m), 1.88-1.61 (m), 0.84-0.81 (m); MS APCI, m / z = 678 (M +).

EXAMPLE 10 N - [(S) -2- (3,4-Dichlorophenyl) -4- [4 - [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-ethyl-3-siane-2 -methoxy-1-naphtamide.

The N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -l-piperidinyl] butyl] -N-ethylamine was reacted with sodium chloride. -cyano-2-methoxy-l-naphthoyl according to the standard acylation methodology to give the title compound which was converted to the hydrochloride salt; mp 160-180 ° C (dec); lE NMR (300 MHz, DMSO-d6) d 10.7 (br., 1H), 8.67 (m, 1H), 8.05 (m, 1H), 7.8-6.4 (m, 9H), 3.4 (s, 3H), 2.6 (s, 3H), 2.0 (, 6H), 1 (m, 3H); MS APCI, m / z = 676 (M +). The required N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methyl-sulfinylphenyl] -1-piperidinyl] butyl] -N-ethylamine was prepared as follows . N- [(S) -2- (3,4-dichlorophenyl) -4-hydroxybutyl] amine (Miller, SC, WO 9512577) was acetylated with acetyl chloride in DCM under standard conditions. Using lithium aluminum hydride the acetamide was reduced to achieve N- [(S) -2- (3,4-dichlorophenyl) -4-hydroxybutyl] -N-ethylamine [XH NMR (300 MHz, CDC13) d 7.4 (d, 1H, J = 10 Hz), 7.15 (d, 1H, J = 5 Hz), 7.0 (d, d, 1H, J = 10.5 Hz), 3.7 (, 1H), 3.6 (m, 1H), 2.9 -2.6 (m, 6H), 1.95 (m, 3H), 1.5 (m, 3H); MS APCI, m / z = 262 (M +)]. Using di (ertbutyl) dicarbonate, the amine was converted to the protected adductor N-Boc [*? NMR (300 MHz, CDC13) d 7.4 (d, 1H, J = 10 Hz), 7.15-7.0 (m, 2H), 1.4 (s, 9H), 1.0 (br s, 3H); MS APCI, m / z = 262 (M-C5H902)], the alcohol was oxidized using oxalyl chloride and DMSO under standard Swern conditions to achieve the aldehyde [IE NMR (300 MHz, CDC13) d 9.7 (s, 1H) , 7.4 (d, 1H, J = 10 Hz), 7.2-7.0 (, 2H), 3.6-2.9 (m, 6H), 1.0 (br., 3H); MS APCI, m / z = 242 (M-C5H902)]. This aldehyde was reacted with 4 - [(S) -2-methylsulfinylphenyl] -piperidine (Shenvi, AB; Jacobs, RT; Miller, SC; Ohnmacht, CJ, Jr.; Veale, CA. WO 9516682) under alkylation conditions standard reductive to provide N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methyl-sulfinylphenyl] -l-piperidinyl] butyl] -N-ethyl-N -tert-butyl carbamate [? E NMR (300 MHz, CDC13) d 8.0 (m, 1H), 7.5-7.3 (m, 5H), 7.0 (, 1H), 3.0 (m, 7H), 2.7 (s, 3H), 2.2 (m, 2H), 2.0-1.6 (m, 10H), 1.4 (s, 9H), 1.0 (m, 3H); MS APCI, m / z = 597 (M +)]. This material was converted to the desired amine by removing the Boc protecting group using trifluoroacetic acid under standard conditions to provide N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S)] -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-ethylamine [1 H NMR (300 MHz, CDC13) d 9.6 (br., 1H), 8.3 (br., 1H), 7.95 (d, 1H, J = 10 Hz), 7.5 (d, 1H, J = 10 Hz), 7.4 (d, 1H, J = 10 Hz), 7.3 (d, 1H, J = 5 Hz), 7.05 (d, d, 1H, J = 10.5 Hz), 3.85 (m, 1H), 3.4 (m, 3H), 3.2 (m, 3H), 2.9 (s, 3H), 2.2 (, 4H), 1.4 (t, 3H, J "= 10 Hz); MS APCI, m / z = 567 (M +)], this material was used without purification.

Example 11 N- [2- (S) - (3,4-dichlorophenyl) -4-hydroxybutyl] -N-methyl-3-cyano-2-methoxy-1-naphtamide.

A solution of N- [(S) -2- (3,4-dichlorophenyl) -4-hydroxybutyl] -N-methylamine (Miller, SC; WO 9512577) in DCM was combined with a 10% aqueous sodium bicarbonate solution. %. The mixture was cooled to 0 ° C and a solution of 3-cyano-2-methoxy-1-naphthoyl chloride in DCM was added dropwise over 30 min. After stirring overnight at room temperature, the organic phase was concentrated and purified by column chromatography to achieve N- [2- (S) - (3,4-Dichlorophenyl) -4-hydroxybutyl] -N-methyl- 3-cyano-2-methoxy-1-naphthamide. 1H NMR (300 MHz, DMSO-d6) d 9.70-9.64 (m), 8.67-8.57 (m), 8.07-7.97 (m), 7.80 (s), 7.72-7.55 (m), 7.52-7.48 (m), 7.40-7.33 (m), 7.12-7.10 (d) , 7.04-7.02 (d), 6.87-6.83 (m), 6.37-6.29 (d), 4.53-4.44 (t), 4.11-4.00 (m), 3.94 (s), 3.92 (s), 3.91-3.73 ( m), 3.71 (s), 3.45-3.38 (m), 3.33 (s), 3.14 (s), 2.97-2.95 (d), 2.63 (s), 2.60 (s); MS APCI, m / z = 455 (M +).

Example 12 N- [2- (S) - (3,4-dichlorophenyl) -4-oxobutyl] -N-methyl-3-cyano-2-methoxy-1-naphtamide.

The product of example 11 was oxidized using oxalyl chloride and DMSO under standard Swern conditions to achieve the title compound. XH NMR (300 MHz, DMSO-de) d 9.70-9.64 (m), 8.67-8.57 (m), 8.07-7.97 (m), 7.80 (s), 7.72-7.55 (), 7.52-7.48 (m), 7.40-7.33 (m), 7.12-7.10 (d), 7.04-7.02 (d), 6.87-6.83 (m), 6.37-6.29 (d), 4.53-4.44 (t), 4.11-4.00 (m), 3.94 (s), 3.92 (s), 3.91-3.73 (m), 3.71 (s), 3.45-3.38 (m), 3.33 (s), 3.14 (s), 2.97-2.95 (d), 2.63 (s), 2.60 (s); MS APCI, m / z = 455 (M +).

Example 13 N- [2- (S) - (3,4-dichlorophenyl) -4,4- (dimethoxy) butyl] -N-methyl-3-cyano-2-oxi-1-naphthamide.

The product of Example 12 (300 mg) was reacted with 2,2-dimethoxypropane (0.16 mL) and 4-toluenesulfonic acid (6 mg) in DCM (5 mL) according to the methods of Lorette et al., J. Org. . Chem., 1960, 25, 521 to give the title compound. XH NMR (300 MHz, DMSO-d6) d 8.64-8.62 (m), 8.08-7.98 (m), 7.75-7.58 (m), 7.39-7.37 (m), 7.13-7.06 (m), 6.96-6.92 ( d), 6.88-6.84 (m), 6.35-6.32 (d), 4.50-4.42 (t), 4.14-4.11 (m), 3.94 (s), 3.92-3.75 (m), 3.69 (s), 3.45- 3.39 (m), 3.23 (s), 3.16 (s), 3.05-3.00 (m), 2.93-2.85 (m), 2.60 (s), 2.04-1.92 (m); MS APCI, m / z = 471 (M-OCH3).

Example 14 N- [2- (S) - (3,4-Dichlorophenyl) -4-methoxy-benzyl] -N-methyl-3-cyano-2-methoxy-1-naphtamide.

The product of Example 11 (130 mg) was reacted with sodium hydride with 60% dispersion (21 mg) and methyl iodide (0.019 mL) in DMF (2 L) to give the title compound. XH NMR (300 MHz, DMSO-d6) d 8.64-8.62 (m), 8.08-7.97 (m), 7.73-7.68 (m), 7.65-7.33 (m), 7.07-7.04 (m), 6.93-6.90 ( d), 6.83-6.80 (m), 6.33-6.30 (d), 4.54-4.46 (t), 4.08-4.01 (m), 3.94 (s), 3.79-3.76 (m), 3.68 (s), 3.44- 3.23 (), 3.19 (s), 3.16-2.89 (m), 2.60 (s), 2.02-1.82 (m), 1.36-0.83 (m); MS APCI, m / z = 471 (M +).

Example 15 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-3-cyano citrate -2-methyl-1-naftamid.

Using standard acylation conditions, 3-cyano-2-methyl-1-naphthoyl chloride (0.109 g) (prepared from 3-cyano-2-methyl-1-naphthoic acid using oxalyl chloride under standard conditions) was reacted with N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine (0.200 g), became to the citrate salt to give the title compound (0.138 g) as a light yellow powder. MS APCI, m / z = 646 (M + H); XH NMR (300 MHz, CDC13) d 8.23-8.17 (), 8.01-7.96 (m), 7.84-7.80 (m), 7.62-7.29 (m), 7.10 (d), 6.96 (d), 6.79 (d) , 6.50 (d), 4.60-4.52 (m), 4.19-4.11 (m), 3.85-3.79 (m), 3.56-3.50 (m), 3.34-3.15 (m), 3.04-2.88 (m), 2.74- 2.53 (m), 2.32-1.60 (m); calculated for C36H3C12N302S, 1 C6H807, 1.3 H20, C 58.51, H 5.56, N 4.87, found C 58.50, H 5.46, N 4.82. The required 3-cyano-2-methyl-1-naphthoic acid was prepared as follows. (a) Methyl-3-cyano-2-hydroxy-l-naphthoate.

A flame-dried, 250 L 3-necked flask was charged with magnesium metal (2.42 g, 99.5 mmol). After cooling to room temperature, diethyl ether (80 mL), benzene (30 mL) and iodine (12.62 g, 49.7 mmol) were added. The reaction mixture was heated under reflux for 2 h and the color of the iodine was dissipated. After cooling to room temperature, this solution was transferred to methyl-3-cyano-2-methoxy-1-naphthoate (10 g, 41.4 mmol) in benzene (30 mL) via syringe. The flask was washed with benzene (15 mL) and a yellow precipitate formed during the addition. The reaction mixture was heated under reflux for a further 1 h. INN of HCl and EtOAc was added and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with saturated Na2S20, NaCl, water, dried over MgSO4, filtered and concentrated. The crude product was purified by chromatography (DCM) to achieve the product (6.88 g, 73% yield) as a yellow solid. 1H NMR (CDC13) d 12.82 (s, 1H), 8.81-8.78 (d, 1H), 8.32 (s, 1H), 7.83-7.82 (d, 1H), 7.70 (t, 1H), 7.50 (t, 1H), 4.16 (s, 3H) ). MS (APCI, negative ion mode) m / z 225.92 (M-). (b) Methyl-3-cyano-2-trifluoromethanesulfonyloxy-1-naphthoate. To a solution of methyl-3-cyano-2-hydroxy-l-naphthoate (6.24 g, 27.5 mmol) in DCM (140 mL) was added triethylamine (4.21 mL, 30.2 mmol) followed by trifluoromethanesulfonic anhydride (5.05 mL, 30.2 mmol) at 0 ° C. The reaction mixture was stirred at room temperature for 30 min. Saturated NaHCO3 was added and the aqueous layer was extracted with DCM. The combined organic extracts were dried over MgSO4, filtered and concentrated. The crude product was purified by chromatography (eluting with DCN) to give the product (9.6 g, 97% yield) as a yellow oil. XH NMR (CDC13) d 8.44 (s, 1H), 8.29-8.04 (d, 1H), 7.01-7.98 (d, 1H), 7.84 (m, 2H), 4.10 (s, 3H). (c) Methyl-3-cyano-2-methyl-1-naphthoate. A stirred solution of methyl-3-cyano-2-trifluoromethanesulfonyloxy-1-naphthoate (0.28 g, 0.779 mmol), K3P04 (0.33 g, 1.55 mmol), methylboronic acid (0.096 g, 1.55 mmol) and (1, 1 '- bis (diphenylphosphino) ferrocene) -dichloropalladium (II) CH2C12 (64 mg, 0.078 mmol) in THF (8 mL) was heated at 66 ° C for 4.5 h. Saturated aqueous NaHCO3 was added and the mixture was extracted with EtOAc (3x). The combined organic layers were dried over MgSO4, filtered and concentrated. The crude product was purified by chromatography (eluting with 5%, 8% EtOAc / hexane) to give the product (0.139 g, 78% yield) as a white solid. 1H NMR (CDC13) d 8.28 (s, 1H), 7.88 (d, 1H), 7.77 (d, 1H), 7.67 (t, 1H), 7.55 (t, 1H), 4.08 (s, 3H), 2.66 ( s, 3H). MS m / z 226 (M +). (d) 3-Cyano-2-methyl-1-naphthoic acid. A solution of methyl-3-cyano-2-methyl-1-naphthoate (0.139 g) in THF (7.55 mL) and water (3 mL) was treated with a solution of NaOH (1.3 mL, IN). Methanol (0.5 mL) was added, and the mixture was stirred under reflux for 27 hours. The mixture was concentrated, treated with additional water and extracted with DCM. The aqueous layer was acidified with 1N HCl and extracted with EtOAc. The extracts were dried, filtered, and the solvent was removed to achieve the product (0.1 g, 77% yield) as a white solid. X H NMR (300 MHz, DMSO-d 6) d 14.02 (s, 1 H), 8.67 (s, 1 H), 8.08 (d, 1 H), 7.87-7.62 (m, 3 H), 2.59 (s, 3 H); MS APCI (negative ion mode) m / z 210.

Example 16 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsul inyl] -1-piperidinyl] butyl] -N-methyl-3 citrate -bromo-2, 4-dim oxy-1-na amide.

Using standard acylation conditions, 3-bromo-2,4-dimethoxy-l-naphthoyl chloride (0.212 g) (prepared from 3-bromo-2,4-dimethoxy-l-naphthoic acid using oxalyl chloride under standard conditions) was reacted with N- [(S) -2- (3,4-dichlorophenyl) -4- [4 - [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine (0.271 g), was converted to the citrate salt, and was isolated from the diethyl ether by filtration to achieve the title compound (0.433 g) as a light yellow powder. MS APCI, m / z = 747 (M + H); XH NMR (300 MHz, CDC13) d 8.08-7.97 (m), 7.57-7.20 (m), 7.01-6.93 (m), 6.60-6.56 (m), 4.46-4.38 (m), 4.04-3.57 (m) , 3.37-2.94 (m), 2.74-2.60 (), 2.33-1.61 (m); calculated for C36H39BrCl2N20 S, 1 CeH80, 0. 8 H20, C 52. 93, H 5.14, N 2.94, found C 52.96, H 5.01, N 2.93.

The requisite 3-bromo-2,4-dimethoxy-l-naphthoic acid was prepared as follows. (a) Ethyl-3-bromo-2, -hydroxy-1-naphthoate. To a solution of ethyl-2,4-dihydroxy-1-naphthoate (A. Bruggink and A. McKillop Tetrahedron Vol. 31, 2607, 1975) (0.1 g, 0.43 mmol) in acetonitrile (2 mL) was added N- bromosuccinimide (84 mg, 0.47 mmol). The mixture was stirred at room temperature for 30 min. The acetonitrile was evaporated and CC1 was added. The solution was filtered and concentrated. The crude product was purified by chromatography (eluting with DCM) to give the product (0.13 g, 93% yield) as a white solid. XE NMR (CDC13) d 13.61 (s, 1H), 8.79 (d, 1H), 8.24 (d, 1H), 7.58 (t, 1H), 7.41 (t, 1H), 6.61 (s, 1H), 4.60 ( q, 2H), 1.55 (t 3H). MS APCI (negative mode) m / z 310.84. (b) Ethyl-3-bromo-2,4-dimethoxy-1-naphthoate. To a solution of ethyl-3-bromo-2,4-dihydroxy-l-naphthoate (5.8 g, 18.6 mmol) in acetone (93 mL) was added potassium carbonate (6.43 g, 46.6 mmol) and dimethyl sulfate (4.4 mL, 46.6 mmol). The mixture was heated under reflux overnight and the solvent was evaporated. Water and EtOAc were added and the organic layer was dried over MgSO, filtered and concentrated. The crude product was purified by chromatography (eluting with 3-5% EtOAc / hexane) to give the product (6.23 g, 99% yield) as a slightly yellow oil. XH NMR (CDCl 3) d 8.13 (d, 1H), 7.83 (d, 1H), 7.62-7.48 (m, 2H), 4.54 (q, 2H), 4.02 (s, 3H), 4.00 (s, 3H), 1.46 (t.3H). (c) 3-Bromo-2,4-dimethoxy-l-naphthoic acid A solution of ethyl-3-bromo-2A4-dimethoxy-1-naphthoate (0.613 g) in THF (6 mL) and water (4 mL) was added. treated with LiOH monohydrate (0.16 g). Methanol (0.5 mL) was added, and the mixture was stirred under reflux for 40 h. The mixture was concentrated, treated with additional water and extracted with DCM. The aqueous layer was acidified with IN of HCl and extracted with EtOAc. The extracts were dried, filtered, and the solvent was removed to achieve the product (0.33 g, 59% yield) as a white solid. 1 H NMR (300 MHz, DMSO-de) d 13.73 (s, 1 H), 8.09 (d, 1 H), 7.82 (d, 1 H), 7.71-7.56 (m, 2 H), 3.97 (s, 3 H), 3.91 ( s, 3H).

Example 17 N- [(S) -2- (3, -dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-3-siazole citrate 2-ethyl-4-methoxy-1-naphtamide.

With the use of standard acylation conditions, 3-cyano-2-ethyl-4-methoxy-1-naphthoyl chloride (0.15 g) was reacted (3-cyano-2-ethyl-4-methoxy-1 acid preparation). -naphthoic using oxalyl chloride under standard conditions) with N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -l-piperidinyl] butyl] - N-methylamine (0.23 g), was converted to the citrate salt, and isolated by filtration of the diethyl ether to obtain the title compound (0.117 g) as a white powder. MS APCI, m / z = 690 (M + H); -? NMR (300 MHz, CDC13) d 8.34-8.13 (m), 8.00-7.30 (m), 7.10-6.99 (m), 6.81-6.51 (), 4.53-4.22 (m), 4.70-2.56 (m), 2.30 -1.08 (m); calculated for C38H? Cl2N303S, 1 C6H807, 1.6 H20, C 57.97, H 5.77, N 4.61, found C 57.98, H 5.62, N 4.46. The required 3-cyano-2-ethyl-4-methoxy-l-naphthoic acid was prepared as follows. (a) Ethyl-3-cyano-2,4-dimethoxy-1-naphthoate. To a solution of ethyl-3-bromo-2,4-dimethoxy-1-naphthoate (Example 16) (11.2 g, 33.0 mmol) in DMF (88 L) was added CuCN (3.00 g, 33.5 mmol) and 2 drops of pyridine. The reaction mixture was placed in a preheated oil bath (185 ° C) and heated for 6 hours. The hot solution was poured into concentrated NHOH (130 mL) containing 130 g of ice. The resulting suspension was extracted with DCM, washed with 1 N HCl, water, dried over MgSO4., filtered and concentrated. The crude product was purified by chromatography (eluting with 3-8% EtOAc / hexane) to give the product (3.81 g, 40% yield) as a white solid. XH NMR (CDC13) d 8.20 (d, 1H), 7.87 (d, 1H), 7.65 (t, 1H), 7.50 (t, 1H), 4.52 (q, 2H), 4.36 (s, 3H), 4.09 ( s, 3H), 1.48 (t 3H). (b) Ethyl-3-cyano-2-hydroxy-4-methoxy-1-naphthoate. According to the method described for example 15 step (a), ethyl-3-cyano-2,4-dimethoxy-1-naphthoate (3.71 g, 13.0 mmol) was converted to the title compound (1.89 g, 54% yield) ) as a yellow solid. ^ "H NMR (CDC13) d 13.37 (s, 1H), 8.79 (d, 1H), 8.24 (d, 1H), 7.66 (t, 1H), 7.42 (t, 1H), 4.58 (q, 2H), 4.49 (s, 3H), 1.54 (t, 3H); MS m / z 272.02 (M +). (c) Ethyl-3-cyano-4-methoxy-2-trifluoromethanesulfonyloxy-1-naphthoate. According to the method described for Example 15 step (b), ethyl-3-cyano-2-hydroxy-4-methoxy-1-naphthoate (1.89 g, 6.97 mmol) was converted to the title compound (2.85 g, quantitative) like a yellow oil. 1 H NMR (CDC13) d 8.31 (t, 2 H), 7.80 (t, 1 H), 7.69 (t, 1 H), 4.54 (q, 2 H), 4.45 (s, 3 H), 1.46 (t, 3 H). (d) Ethyl-3-cyano-4-methoxy-2-vinyl-l-naphthoate. To a solution of ethyl 3-cyano-4-methoxy-2-trifluoromethanesulfonyloxy-1-naphthoate (1.84 g, 4.56 mmol) in 21 mL of dry dioxane was added tributylvinyltin (1.47 mL, 5.03 mmol), LiCl (0.58 g, 13.7 mmol), Pd (PPh3) 4 (0.11 g, 0.09 mmol) and a few crystals of 2,6-di-t-butyl-4-methylphenol. The resulting suspension was heated under reflux for 3 hours. The mixture was cooled to room temperature and treated with a saturated KF solution (30 mL) and stirred for 30 min. After dilution with EtOAc, the mixture was filtered, washed with water and saturated NaCl, dried over MgSO4, filtered and concentrated. After chromatographic purification (hexane, 3% and 4% EtOAc / hexane), the product was obtained as a white solid (1.09 g, 85% yield). XH NMR (CDC13) d 8.24 (d, 2H), 7.86 (d, 1H), 7.63 (m, 2H), 7.01 (d, 1H), 5.83 (d, 1H), 5.70 (d, 1H), 4.48 ( q, 2H), 4.28 (s, 3H), 1.41 (t, 3H). MS m / z 282.04 (M +). (e) Ethyl-3-cyano-2-ethyl-4-methoxy-1-naphthoate. To a solution of ethyl-3-cyano-4-methoxy-2-vinyl-1-naphthoate (1.09 g, 3.87 mmol) in 75 mL of ethanol was added 5% Pd / C (0.16 g). The solution was stirred at room temperature for 2 h under hydrogen at 50 psi. The solution was filtered and washed with ethanol and evaporated to give the product as a yellow solid (1.09 g, 99% yield). 1 H NMR (CDCl 3) d 8.20 (d, 1 H), 7.74 (d, 1 H), 7.66 (t, 1 H), 7.55 (t, 1 H), 4.53 (q, 2 H), 4.27 (s, 3 H), 2.96 ( q, 2H), 1.46 (t, 3H), 1.35 (t, 3H); MS m / z 284.04 (M +). (f) 3-Cyano-2-ethyl-4-methoxy-1-naphthoic acid. A solution of ethyl-3-cyano-2-ethyl-4-methoxy-1-naphthoate (1.09 g) in THF (13 mL) and water (9 mL) was treated with LiOH monohydrate (0.34 g). Methanol (0.5 mL) was added, and the mixture was stirred under reflux for 22 hours. The mixture was concentrated, treated with additional water and extracted with DCM. The aqueous layer was acidified with IN of HCl and extracted with EtOAc. The extracts were dried, filtered, and the solvent was removed to provide the crude product. The crude product was purified by chromatography (eluting with 1-5% MeOH in DCM with 1% HOAc) to give the product (0.14 g, 14% yield) as a yellow solid. LH NMR (300 MHz, DMSO-de) d 13.86 (s, 1H), 8.20 (d, 1H), 7.84 (m, 2H), 7.69 (t, 1H), 4.19 (s, 3H), 2.88 (q, 2H) , 1.31 (t, 3H) MS APCI (negative mode) m / z 253.88.

Example 18 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulphenylphenyl] -1-piperidinyl] butyl] -N-methyl-3-cyano citrate -2-ethyl-1-naphtamide.

Using standard acylation conditions, the 3-cyano-2-ethyl-1-naphthoyl chloride (1.33 g) (prepared from 3-cyano-2-ethyl-1-naphthoic acid using oxalyl chloride under standard conditions) was reacted with N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinyl-phenyl] -1-piperidinyl] butyl] -N-methylamine (2.29 g), and converted to the citrate salt to achieve the title compound (3.57 g) as a light yellow powder. MS APCI, m / z = 660.32 (M + H); ? E NMR (300 MHz, CDC13) d 8.31-8.19 (m), 7.99-7.82 (m), 7.57-7.31 (m), 7.14-7.11 (d), 7.00-6.98 (m), 6.80 (d), 6.53-6.50 (m), 4.60 (t), 4.38 (t), 3.69-3.49 (m), 3.32-2.55 (m), 2.37-1.61 (m), 1.39-1.10 (m); calculated for C37H39C12N302S, 1 C6H807, 1.35 H20, C 58.88, H 5.71, N 4.79, found C 58.86, H 5.57, N 4.70. The requisite 3-cyano-2-ethyl-1-naphthoic acid was prepared as follows. (a) Methyl-3-cyano-2-ethyl-1-naphthoate. To a solution of methyl-3-cyano-2-vinyl-l-naphthoate (Example 24) (5.98 g, 25.2 mmol) in 500 mL of ethanol was added 5% of Pd in carbon (1.5 g). The solution was shaken at room temperature for 6 h under hydrogen at 50 psi. The solution was filtered and washed with ethanol. The ethanol was evaporated to give the product as a yellow solid (5.39 g, 89% yield). XE NMR (300 MHz, CDC13) d 8.28 (s, 1H), 7.89 (d, 1H), 7.76 (d, 1H), 7.67 (t, 1H), 7.55 (t, 1H), 4.07 (s, 3H) , 2.96 (q, 2H), 1.37 (t, 3H); MS m / z 239.98 (M + H). Alternatively, methyl-3-cyano-2-ethyl-1-naphthoate can be prepared by the reaction of methyl-3-cyano-2-tri-fluoromethanesulfonyloxy-1-naphthoate (Example 15 (b)) according to the procedure described for Example 15 (b) except the use of triethylborane in place of methylboronic acid. (b) 3-Cyano-2-ethyl-1-naphthoic acid. A solution of methyl-3-cyano-2-ethyl-1-naphthoate (4.87 g, 20.4 mmol) in 10 g of trimethylsilyl iodide was heated at 75 ° C overnight. 1N HCl was added and the mixture was extracted with EtOAc. The combined organic layers were dried, filtered and concentrated. The crude product was purified by chromatography (5% MeOH / DCM with 1% HOAc) to achieve the product (4.35 g, 95% yield) as a yellow solid. H NMR (300 MHz, DMSO-de) d 14.03 (s, 1H), 8.69 (s, 1H), 8.17-8.09 (dd, 1H), 7.89-7.77 (m, 2H), 7.69 (t, 1H), 2.91 (q, 2H), 1.29 (t, 3H) ); MS (APCI negative ion mode) m / z 223.90.

Example 19 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [2-methylsulfonyl-enyl] -1-piperidinyl] butyl] -N-methyl-3-cyano-2- citrate ethyl-1-naphtamide.

Using standard reductive amination conditions, N- [(S) -2- (3,4-dichlorophenyl) -4-oxo-butyl] -N-methyl-3-cyano-2-ethyl-1-naphthamide (0.301 g) ) was reacted with 4- (2-methyl-sulfonyl-phenyl) -1-piperidine (0.162 g), and converted to the citrate salt to achieve the title compound (0.359 g) as a white powder. MS APCI m / z = 577 (M + H); XH NMR (300 MHz, CDC13) d 8.25-8.19 (m), 8.06 (m), 7.84-7.82 (m), 7.63-7.34 (m), 7.13 (d), 7.00-6.97 (d), 6.81-6.80 (d), 6. 52-6.45 (m), 4.61 (t), 4.44-4.35 (m), 3.68-3.64 (m), 3.50-2.55 (m), 2.32-1.74 (), 1.59 (s), 1.39-1.07 (m); calculated for C37H39CI2N3O3S, 1.0 C6H807, 0.8 H20, C 58.47, H 5.55, N 4.76, found C 58.54, H 5.44, N 4.62. The required N- [(S) -2- (3,4-dichlorofenyl) -4-oxobutyl] -N-methyl-3-cyano-2-ethyl-1-naphine was prepared as follows. (a) N- [(S) -2- (3,4-Dichlorophenyl) -4-hydroxybutyl] -N-methyl-3-cyano-2-ethyl-1-naphine. To a stirred, cooled mixture (0 ° C) of (S) -2- (3,4-dichlorophenyl) -4-hydroxybutyl-N-methylamine (0.882 g, 3.55 mmol) in DCM (25 mL) and 1N NaOH (4.44 mL) was added dropwise a solution of 3-cyano-2-ethyl-1-naphthoyl chloride (0.866 g, 3.55 mmol) in DCM (10 mL). The mixture was stirred at 0 ° C for 2.5 h, H20 and DCM were added and the mixture was extracted with DCM. The combined organic layers were dried, filtered and concentrated. Purification by chromatography (0%, 50%, 100% EtOAc in Et20) gave the title compound (1.25 g, 77%) as a white solid. ? E NMR (300 MHz, CDC13) d 8.28-8.18 (m), 7.86-7.79 (m), 7.61-7.45 (m), 7.37-7.31 (m), 7.08-7.05 (d), 6.96-6.94 (d) ), 6.76 (d) 7 6.50-6.44 (m), 4.64-4.56 (m), 4.42 (m), 3.71-3.03 (m), 2.73-2.69 (m), 2.58-2.55 (d), 2.05-1.63 (m), 1.52-1.16 (m); MS m / z 455.23 (M + H). (b) N- [(S) -2- (3,4-Dichlorophenyl) -4-oxobutyl] -N-methyl-3-cyano-2-ethyl-1-naphtamide. To a stirred (-78 ° C) stirred solution of oxalyl chloride (0.33 mL, 3.78 mmol) in DCM (lOmL) was added DMSO (0.54 mL, 7.58 mmol) in DCM (5 mL) per drop. The solution was stirred at -78 ° C for 5 min and a solution of N- [(S) -2- (3,4-dichlorophenyl) -4-hydroxybutyl] -N-methyl-3-cyano- was added dropwise. 2-ethyl-1-naphthamide (1.15 g, 2.52 mmol) in DCM (6.0 mL) and DMSO (2.9 mL). The solution was stirred at -78 ° C for 15 min and triethylamine (2.11 mL, 15.1 mmol) was added. Stirring was continued at -78 ° C for 30 min and then at room temperature for 2 h. INN of HCl (75 mL) and DCM (75 mL) were added and the organic layer was dried (MgSO4), filtered, and concentrated. Purification by chromatography (50% Et20 in DCM) afforded the title compound (1.01 g, 89%) as a white pasty solid. ? E NMR (300 MHz, CDC13) d 9.78 (s), 9.57 (s), 8.28-8.19 (m), 7.92- 7.78 (m), 7.61-7.46 (m), 7.39-7.29 (m), 6.99-6.97 (d) ), 6.94-6.91 (d), 6.73 (d), 6.51-6.47 (dd), 6.38 (d), 4.68-4.54 (m), 3. 82-3.80 (m), 3.61-3.45 (m), 3.34-3.27 (m), 3.08-2.91 (m), 2. 71-2.52 (m), 2.06-2.02 (m), 1.35-1.29 (m), 1.08-1.03 (t); MS m / z 453.15 (M + H).

Example 20 N- [2- (S) - (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -3-cyano-2-methoxy citrate -1-naphtamide.

The 3-cyano-2-methoxy-l-naphthoic acid (155 mg) was reacted with oxalyl chloride under standard conditions to achieve the acid chloride and used without purification. The acid chloride was combined with N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -amine (300 mg) and triethylamine under standard acylation conditions to achieve the product as a white powder (300 mg, 67%) after extraction and chromatographic purification (5% methanol in DCM), and converted to the citrate salt under standard conditions. 1 H NMR (300 MHz, DMSO-de) d 8.76-8.61 (m), 8.56 (s), 8.02-8.00 (d), 7.84-7.80 (m), 7.69-7.55 (m), 7.53-7.47 (m), 7.45-7.25 (m), 7.19-7.17 (d), 3.89 (s), 3.86-3.75 (m), 3.56-3.50 (m), 3.44-3.27 (m), 3.07-3.04 (m), 2.94-2.90 (m), 2.82-2.79 (m) , 2.65 (s), 2.22-2.15 (m), 2.13-1.92 (m), 1.76-1.39 (m); MS APCI, m / z = 648 (M +).

The required N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1- piperidinyl] butyl] -amine was prepared as follows. (a) [2- (S) - (3,4-dichlorophenyl) -4- [4- [(S) -2- (methylisulfinyl) phenyl] -1-piperidinyl] butyl] -phthalimide. 4- [(S) -2-methylsulfinylphenyl] -piperidine (5.06 g) was reacted with N- [(S) -2- (3,4-dichlorophenyl) -4-oxobutyl] -phthalimide (Bernstein, PR; Miller, SC, EP 709376, 1996) (8.2 g) in the presence of sodium cyanoborohydride under standard reductive amination conditions to achieve the product (6.0 g, 46%) after chromatographic purification and extraction (5% methanol in DCM). 1 H NMR (300 MHz, DMSO-de) d 7.85-7.78 (m), 7.57-7.56 (d), 7.53-7.46 (m), 7.41-7.38 (m), 7.24-7.19 (dd), 3.86-3.75 ( m), 3.39-3.34 (m), 3.19-3.16 (m). 2.89-2.85 (d), 2.79-2.75 (d), 2.64 (s), 2.62-2.57 (m), 2.19-2.15 (m), 2.10-2.08 (m), 1.90-1.79 (m), 1.69-1.54 (m); MS APCI, m / z = 569 (M +). (b) N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -amine. [2- (S) - (3,4-dichlorophenyl) -4- [4- [(S) -2- (methylsulfinyl) phenyl] -1-piperidinyl] butyl] -phthalimide (6.13 g) was dissolved in methanol (100 mL), hydrazine (0.8 mL) was added dropwise and the mixture was heated under reflux for min. The reaction mixture was cooled to room temperature and quenched with water, diluted with DCM, extracted with saline, dried (MgSO4), and concentrated to provide the amine as a glassy solid (4.7 g, quantitative) After chromatographic extraction and purification (5-10% methanol, 1% NHOH, in DCM). 1 H NMR (300 MHz, DMSO-d 6) d 7.85-7.81 (m), 7.56-7.40 (m), 7.25-7.19 (dd), 3.39-3.20 (m), 2.93-2.89 (m), 2.82-2.71 ( m), 2.65 (s), 2.30-2.07 (m), 1.93-1.87 (m), 1.71-1.57 (m); MS APCI, m / z = 439 (M +).

EXAMPLE 21 N- [2- (S) - (3,4-Dichlorophenyl) -4- [4- (S) -2-methylsulfinylphenyl] -1-piperidinyl] -butyl] -N-methyl-3-cyano Citrate -2- (1-propenyl) -1-naphtamide.

Using standard acylation conditions, 3-cyano-2- (1-propenyl) -1-naphthoyl chloride (0.028 g) (prepared from 3-cyano-2- (1-propenyl) -1-naphthoic acid using oxalyl under standard conditions) was reacted with N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N- methylamine (0.055 g), and converted to the citrate salt to provide the title compound as a white powder. MS APCI, m / z = 672 (M +); 1 H NMR (300 MHz, CDC13) d 8.22 (d), 7.93-7.80 (m), 7.51 (m), 6.61-6.47 (m), 3.49 (m), 3.43-3.21 (m), 2.72-2.36 (m) ), 2.00-1.93 (m); mp 112 ° C. The required 3-cyano-2- (1-propenyl) -1-naphthoic acid was prepared as follows. (a) Methyl-3-cyano-2-allyl-1-naphthoate.

To a stirred solution of methyl-3-cyano-2-trifluoromethanesulfonyloxy-1-naphthoate (Example 15) (0.310 g0.86 mmol), anhydrous lithium chloride (0.307 g, 7.25 mmol), triphenylphosphine (0.136 g, 0.52 mmol) and dichlorobis (triphenylphosphine) palladium (II) (0.073 g, 0.10 mmol) in DMF (10 mL) were added. added allyltributyltin (0.535 mL, 1.73 mmol). A crystal of 2,6-di-tert-butyl-4-methylphenol was added and the mixture was heated under nitrogen at 120 ° C for 45 min. Water (15 mL) and diethyl ether (15 mL) were added and the organic phase was washed successfully with IN of HCl (3 x 50 mL) saturated aqueous KF (3 x 50 mL), dried (Na 2 SO), filtered, This was concentrated and purified by column chromatography (15% ether / hexane) to obtain the product as a colorless oil (0.040 g, 14%). 1H NMR (300 MHz, CDC13) d 8.28 (s, 1H), 7.89 (d, 1H), 7.81 (d, 1H), 7.71 (m, 1H), 7.65 (m, 1H), 6.04-5.91 (m, 1H), 5.18 (m, 1H), 4.05 (s, 3H), 3.73 (m, 2H). (b) 3-Cyano-2- (1-propenyl) -1-naphthoic acid. A solution of methyl-3-cyano-2-allyl-1-naphthoate (0.040 g, 0.16 mmol) in THF (3 mL) and water (1 mL) was treated with LiOH monohydrate (0.020 g, 0.48 mmol) and MeOH (3 mL) and heated under reflux for 72 hours. The mixture was concentrated, treated with additional water and 1N NaOH and extracted with DCM (3 x 25 mL). The aqueous layer was acidified (IN HCl) and the resulting white precipitate was extracted with DCM (3 x 50 L). The combined organic extracts were dried (Na2SO4), filtered and concentrated to achieve the product as a yellow oil (0.026, 70%). MS APCI, m / z = 236 (M +); ? E NMR (300 MHz, CDC13) d 8.68 (s, 1H), 8.16 (d, 1H), 7.81 (, 2H), 7.70 (m, 1H), 6.69 (d, 1H), 6.44 (m, 1H) , 1.95 (m, 3H).

Example 22 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-3-bromo citrate -2- ethoxy-1-naphtamide.

Using standard acylation conditions, 3-bromo-2-methoxy-1-naphthoyl chloride (0.149 g, 0.50 mmol) (prepared from 3-bromo-2-methoxy-l-naphthoic acid using oxalyl chloride under standard conditions) was reacted with N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [ (S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine (0.226 g, 0.50 mmol), and converted to the citrate salt to provide the title compound (0.150 g, 42%) as a clear powder. "? NMR (300 MHz, CDC13) d 8.36 (m), 7.92-7.75 (m), 7.56-7.40 (m), 6.27 (m), 3.82 (s), 3.59-3.10 (m), 2.89-2.50 (m), 1.81 (m); MS APCI, m / z = 717 (M +). The required 3-cyano-2-methoxy-l-naphthoic acid was prepared as follows. (a) Methyl-2-hydroxy-1-naphthoate To a solution of 2-hydroxy-l-naphthoic acid (15.40 g, 0.082 mol) in acetone (400 mL) was added NaHCO3 (6.88 g, 0.082 mol) followed by dimethylsulfate (23.23 mL, 0.246 mol) and heated under reflux for 1 h. The mixture was cooled to room temperature and quenched with water (150 mL), extracted with DCM, dried, and concentrated to achieve the product (16.05 g, 97%). XH NMR (300 MHz, DMSO-d6) d 10.59 (s, 1H), 7.93 (d, 1H), 7.82 (t, 1H), 7.51 (t, 1H), 7.38 (t, 1H), 7.24 (d, 1H), 3.94 (s, 3H); MS APCI, m / z = 201 (M ~). (b) Methyl-2-hydroxy-5,6,7,8-tetrahydro-l-naphthoate. To a solution of methyl-2-hydroxy-l-naphthoate (16.50 g, 0.082 mol) in acetic acid (225 mL) was added 10% Pd in carbon (1.65 g, 10% by weight) and the mixture was shaken under hydrogen (50 psi) at 60 ° C for 48 h. The mixture was filtered, dried and concentrated to achieve the product (15.99 g, 95%). lE NMR (300 MHz, CDC13) d 10.90 (s, 1H), 7.13 (d, 1H), 6.79 (d, 1H), 3.94 (s, 3H), 2.97 (m, 2H), 2.70 (, 2H), 1.73 (m, 4H); MS (APCI, negative ion mode), m / z = 205 (M-). (c) Methyl-3-bromo-2-hydroxy-5,6,7,8-tetrahydro-l-naphthoate. To a solution of methyl-2-hydroxy-5,6,7,8-tetrahydro-l-naphthoate (10.40 g, 0.050 mol) and sodium acetate (7.44 g, 0.090 mol) in acetic acid (180 mL) were added to the solution. added a solution of bromine (10.47 g, 0.066 mol) in acetic acid (72 mL) per drop. After heating at 80 ° C for 1 h, the reaction mixture was cooled and concentrated. The residue was diluted with water and extracted with EtOAc, dried, concentrated and purified by chromatography (2% EtOAc in hexane) to afford the product as a white solid (11.13 g, 77%). ? E NMR (300 MHz, DMSO-d6) d 9.56 (s, 1H), 7.33 (s, 1H), 3.80 (s, 3H), 2.64 (m, 2H), 2.50 (, 2H), 1.66 (m, 4H); MS APCI, m / z-283 (M +). (d) Methyl-3-bromo-2-methoxy-5, 6, 7, 8-tetrahydro-l-naphthoate. To a solution of methyl-3-bromo-2-hydroxy-5,6,7,8-tetrahydro-1-naphthoate (11.13 g, 0.039 mol) in acetone (250 mL) was added dimethyl sulfate (4.43 L, 0.047 mol) and potassium carbonate (6.48 g, 0.047 mol), and the mixture was heated under reflux overnight. The reaction was cooled to room temperature and triethylamine (25 mL) was added. After stirring for 0.5 h, the mixture was filtered, concentrated, diluted with EtOAc (100 mL), washed successfully with IN of HCl, saturated aqueous NaHCO 3, and saline, and extracted with EtOAc. The combined organic extracts were dried, filtered, concentrated and purified by chromatography (3% of EtOAc in hexane) to achieve the product as a white solid (7.3 g, 63%). XU NMR (300 MHz, CDC13) d 7.31 (s, 1H), 3. 92 (s, 3H), 3.85 (s, 3H), 2.71 (m, 2H), 2.62 (m, 2H), 1.75 (m, 4H). (e) Methyl 3-bromo-2-methoxy-1-naphthoate. A mixture of methyl 3-bromo-2-methoxy-5,6,7,8-tetrahydronaphthalene-1-carboxylate (1.00 g, 3.34 mmol), N-bromosuccinimide (1.31 g, 7.35 mmol) and 2,2'-azobisisobutyronitrile (50 mg) in 10 mL of carbon tetrachloride was stirred under reflux for 18 h. Succinimide was filtered from the cooled mixture and washed well with carbon tetrachloride, and the filtrate was concentrated to yield a yellow oil which consisted primarily of methyl 3,5,8-tribromo-2-methoxy-5,6,7,8-tetrahydronaphthalene-1-carboxylate [XH NMR (CDC13) d 2.33 (d, 2, J = 9Hz), 2.68 (d, 2, J = 12Hz), 3.89 (s, 3), 3.99 (s, 3), 5.54 (bs, 1), 5.83 (bs, 1), 7.62 (s, 1)]. The oil was dissolved in 10 mL of xylene and heated under reflux for 11 h during which time HBr was given. The cooled mixture was concentrated under reduced pressure, the residue was dissolved in DCM, and purified by chromatography (0-5% EtOAc in hexane) to achieve the product (0.48 g, 48%). XH NMR (CDC13) d 3.98 (s, 3), 4.06 (s, 3), 7.46 (t, 1, J = 9Hz), 7.53 (t, 1, J = 9Hz), 7.73 (d, 1, J = 9Hz), 8.15 (s, 1). MS APCI, m / z = 297 (M +). (f) 3-Bromo-2-methoxy-1-naphthoic acid A solution of methyl-3-bromo-2-methoxy-1-naphthoate (0.250 g, 0.85 mmol) in THF (6 mL) and water (2 mL) it was treated with LiOH monohydrate (0.079 g, 1.88 mmol) and MeOH (3 mL) and heated under reflux for 48 hours. The mixture was concentrated, diluted with water and 1N NaOH, then extracted with DCM. The aqueous layer was acidified (INN of HCl) and the resulting white precipitate was extracted with DCM. The combined organic extracts were dried, filtered and concentrated to give the product as a yellow oil (0.230 g, 97%). XE NMR (300 MHz, DMSO-d6) d 13.8 (s, 1H), 8.44 (s, 1H), 7.98 (d, 1H), 7.76 (d, 1H), 7.64-7.57 (m, 2H), 3.91 ( s, 3H); MS APCI (negative ion mode), m / z = 281 (M ").

EXAMPLE 23 N- [2- (S) - (3,4-Dichlorophenyl) -4- [4- [2- (S) -methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-3-cyano Citrate -2- (2, 2, 2-triroethoxy) -1-naphtamide.

A solution of 2- (2,2,2-triroethoxy) -3-cyano-1-naphthoic acid was converted to the corresponding acid chloride using oxalyl chloride under standard conditions. This material (0.063 g) was reacted with N - [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N -methylamine (0.096 g) using standard acylation conditions and converted to the citrate salt. XH NMR (300 MHz, DMSO-d6) d 8.78-8.73 (m), 8.14-6.85 (m), 6.20-6.17 (m), 4.84-4.43 (m), 4.072-1.78 (m); MS APCI, m / z = 730 (M +). The required 2- (2, 2, 2-triroethoxy) -3-cyano-l-naphthoic acid required was prepared as follows, (a) Methyl 2- (2,2,2-triroethoxy) -3-cyano-l-naphthoate . Methyl 3-cyano-2-hydroxy-l-naphthoate (Example 15, step (a)) (0.050 g) and powdered potassium carbonate (0.060 g) were combined in 4 mL dry acetone. 2, 2, 2-triroethyltriflate (0.102 g) was added and the suspension was heated under re for 2 h. The suspension was cooled, filtered and concentrated under reduced pressure to yield a white solid. The solid was dissolved in EtOAc and filtered through a small column of silica gel. The obtained solution was concentrated under reduced pressure to obtain the product (0.075 g) as a white solid. 1 H NMR (300 MHz, CDC13) d 8.31 (s), 7.92-7.88 (m), 7.75-7.69 (dd), 7.65-7.60 (dd), 4.65-4.57 (q), 4.07 (s); 19 F NMR (282 MHz, 1H decoupled, CFC13) d -72.37 (s). (b) 2- (2, 2, 2-Triroethoxy) -3-cyano-l-naphthoate. Methyl 2- (2,2,2-triroethoxy) -3-cyano-l-naphthoate (0.075 g) and the LiOH monohydrate (0.015 g) were dissolved in a solution of 3 mL of THF, 1 mL of water, and 1 L of MeOH. The solution was heated under re for 4 h. The solution was cooled to room temperature and acidified to pH 2 with IN of HCl. The acidified solution became basic (pH 8) with saturated aqueous NaHCO3 and kept stirring overnight. The solution was transferred to a separatory funnel, 15 mL of water was added, and the solution was extracted with 30 mL of diethyl ether. The aqueous phase was acidified to pH 2 with IN of HCl. The white suspension was extracted with EtOAc. The EtOAc layer was washed with saline, dried with Na 2 SO 4, filtered, and concentrated under reduced pressure to yield the product (0.057 g) as a white solid. 1 H NMR (300 MHz, DMSO-de) d 14.30 (b), 8.79 (s), 8.18-8.12 (d), 7.94-7.91 (d), 7.86-7.81 (dd), 7.75-7.69 (dd), 4.90 -4.79 (q) • Example 24 N- [(S) -2- (3, -dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-3-cyano- citrate 2-vinyl-1-naphtamide.

Using standard acylation conditions, the 3-cyano-2-vinyl-l-naphthoyl chloride (0.086 g) (prepared from 3-cyano-2-vinyl-l-naphthoic acid using oxalyl chloride under standard conditions) was reacted with N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine (0.167 g), and converted to the citrate salt to achieve the title compound (0.220 g) as a clear powder. XH NMR (300 MHz, DMSO-d6) d 8.72-8.64 (), 8.11-5.41 (m), 4.57-4.49 (m), 4.29-4.06 (m), 4.06 (b), 3.69-1.78 (m); MS APCI, m / z = 658 (M +). The required 3-cyano-2-vinyl-l-naphthoic acid was prepared as follows, (a) Methyl 3-cyano-2-vinyl-l-naphthoate. To a solution of methyl 3-cyano-2-triromethanesulfonyloxy-1-naphthoate (Example 15) (0.150 g, 0.417 mmol) in 4 mL of dry dioxane was added tributylvinyltin (0.134 mL, 0.459 mmol), LiCl (0.053 g, 1.252). mmol), Pd (PPh3) 4 (0.024 g, 0.020 mmol) and a few crystals of 2,6-di-t-butyl-4-methylphenol. The resulting suspension was heated under re for 2 h. The mixture was cooled to room temperature and treated with KF solution (1 g of KF in 10 mL of H20) and stirred for 30 min. After dilution with EtOAc, the mixture was filtered, washed with water and saturated NaCl, dried over Na 2 SO 4, filtered and concentrated. After chromatographic purification (0.10% EtOAc in hexane), the product was achieved as a white solid (0.088 g, 88%). 1 H NMR (300 MHz, CDC13) d 8.31 (s), 7.89-7.84 (d), 7.81-7.78 (d), 7.72-7.66 (dd), 7.64-7.56 (dd), 7.07-6.97 (dd), 5.90-5.84 (d), 5.75- 5.71 (d), 4.01 (s). (b) 3-Cyano-2-vinyl-l-naphthoate. Methyl 3-cyano-2-vinyl-l-naphthoate (0.087 g, 0.366 mmol) and LiOH monohydrate (0.023 g, 0.550 mmol) were combined in 3 mL of THF, 1 mL of water, and 1 mL of MeOH . The solution was heated under reflux for 6 h. The solution was cooled, 10 mL of saturated aqueous NaHC 3 was added. The solution was extracted with 20 mL of Et20 and the aqueous phase was acidified with 1N HCl to pH 2 and extracted with EtOAc. The organic phase was washed with saline, dried with Na 2 SO 4, filtered and concentrated under reduced pressure to obtain a white solid. The solid was treated with MeOH and toluene and concentrated under reduced pressure. The solid was once again treated with MeOH and toluene and concentrated under reduced pressure to achieve the product (0.075 g, 91% yield) as a white solid. 1 H NMR (300 MHz, DMSO-dβ) d 14.08 (b), 8.73 (s), 8.14-8.11 (d), 7.89-7.70 (m), 7.06-6.96 (dd), 5.96-5.90 (d), 5.81 -5.77 (d).

Example 25 N- [(S) -2- (3,4-Dichloro-enyl) -4- [4- [2-thiazol-2-yloxyphenyl] -1-piperidinyl] butyl] -N-methyl-3- citrate cyano-2-methoxy-1-naphtamide.

The trifluoroacetate of 4- [2-thiazol-2-yloxyphenyl] -piperidine was reacted with N- [2- (S) - (3,4-dichlorophenyl) -4-oxobutyl] -N-methyl-3-cyano- 2-methoxy-1-naphthamide using standard reductive amination conditions and converted to the citrate salt (25% yield). H NMR (300 MHz, DMSO-d6) d 8.64 (d), 8.03 (m), 7.78-7.19 (m), 7.08-6.80 (m), 6.31 (d), 4.52 (t), 4.06-3.94 (m ), 3.93 (d), 3.92-3.70 (m), 3.54-1.60 (m). MS APCI, m / z = (M +); 699. The required 4- [2-thiazol-2-yloxyphenyl] -piperidine was prepared as follows. (a) 4- [2- [(5-Bromothiazol-2-yl) oxy] phenyl] -1-N-Cbz-1-piperidine. The 2,5-dibromothiazole (430 mg) was dissolved in DMF under nitrogen and thereto was added 4- (2-hydroxyphenyl) -N-Cbz-piperidine (500 mg) and potassium carbonate (670 mg). The reaction was heated to 100 ° C overnight and then allowed to cool. It was diluted with EtOAc; washed with water, saline; dried, filtered and concentrated under reduced pressure. The residue was purified via chromatography (15% EtOAc in hexane) to achieve the desired product (500 mg) as an oil. 1 H NMR (300 MHz, CDC13) d 7.42-7.13 (m, 10H), 5.15 (s, 2H), 4.31 (bs, 2H), 3.00 (m, 1H), 2.85 (t, 2H), 1.79 (d, 2H), 1.63 (m, 2H). MS APCI, m / z = (M +); 473. (b) 4- [2- [Thiazol-2-yloxy] phenyl] -piperidine trifluoroacetate. 4- [2- [(5-Bromothiazol-2-yl) oxy] phenyl] -1-N-Cbz-1-piperidine (500 mg) was dissolved in 2-propanol (20 mL) under nitrogen and this was added 10% palladium on carbon (220 mg). The mixture was shaken under hydrogen, (50 psi) overnight. It was filtered and concentrated under reduced pressure. The residue was then dissolved in TFA (10 mL), heated under reflux for 10 min, cooled and concentrated under reduced pressure. It was partitioned between EtOAc and aqueous sodium bicarbonate, the layers were separated and the organic layer was dried, filtered and concentrated under reduced pressure to achieve the desired compound (370 mg) as a yellow solid. XH NMR (300 MHz, CDC13) d 7.46-7.16 (m, 5H), 6.82 (d, 1H), 3.52 (d, 2H), 3.13 (m, 1H), 2.95 (m, 2H), 2.02 (m, 4H). MS APCI, m / z = (M +); 261 Example 26 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylmethyl] -1-piperidinyl] butyl] -3-cyano-2-methylsulfonyloxy citrate -1-naphtamide. 4- [(S) -2-methylsulfinyl-phenyl] -piperidine (0.215 g, 0.900 mmol) was reacted with N- [2- (S) - (3,4-dichlorophenyl) -4-oxobutyl] -3 -cyano-2-methylsulfonyloxy-1-naphthamide (0.454 g, 0.900 mmol) in the presence of sodium cyanoborohydride under standard reductive amination conditions. The crude product was purified by gradient chromatography (eluting with 2-4% MeOH / DCM) to give the product (0.513 g, 80% yield) as a white solid. XH NMR (300 MHz, CDC13) d 8.25 (s, 1H), 7.90 (m, 2H), 7.68 (m, 4H), 7.43 (m, 4H), 7.16 (dd, 1H), 3.97 (m, 1H) , 3.69 (m, 1H), 3.51 (s, 3H), 3.08 (m, 1H), 2.84 (m, 2H), 2.61 (s, 3H), 2.57 (m, 1H), 2.38 (, 2H), 2.03 -1.70 (m, 4H), 1.68 (m, 1H), 1.31 (m, 3H); MS APCI, m / z = 712 (M +); Analysis calculated for C35H35N3? 5S2Cl2, 1.0 C6H807, 1.0 water, C 53.36, H 4.91, N 4.55, found C 53.31, H 4.86, N 4.49. (a) N- [2- (S) - (3,4-dichlorophenyl) -4-hydroxybutyl] -3-cyano-2-methoxy-1-naphthamide. Using Schotten Baumann conditions, the 3-cyano-2-methoxy-1-naphthoyl chloride (3.99 g, 16.29 mmol) was reacted with N- [2- (S) - (3,4-dichlorophenyl) -4- hydroxybutyl] amine and purified by chromatography (0.5-5% MeOH in DCM) to give the product (5.51 g, 77% yield) as a white solid. XH NMR (300 MHz, CDC13) d 8. 16 (s, 1H), 7.82 (d, 1H), 7.65-7.32 (m, 5H), 7.14 (dd, 1H), 6.18 (t, 1H), 3.98 (s, 3H), 3.8-3.68 (m, 3H), 3.54 (m, 1H), 3.18 (m, 1H), 2.05 (m, 1H), 1.77 (m , 1 HOUR); MS APCI, m / z = 443 (M +). (b) N- [2- (S) - (3,4-Dichlorophenyl) -4-tert-butyldimethylsilyloxybutyl] -3-cyano-2-methoxy-1-naphthamide. Using typical conditions, N- [2- (S) - (3, 4-dichlorophenyl) -4-hydroxybutyl] -3-cyano-2-methoxy-1-naphthamide (5.51 g, 12.46 mmol) was reacted with tert-butyldimethylsilyl chloride (2.81 g, 18.69 mmol) and triethylamine (2.02 g) in DCM, then purified by chromatography (eluting with 50-70% Et20 in hexane) to give the product (6.48 g, 94% yield) as a white solid. XH NMR (300 MHz, CDC13) d 8.2 (s, 1H), 7.82 (d, 1H), 7.62-7.36 (m, 5H), 7.16 (dd, 1H), 6.14 (t, 1H), 4.01 (s, 3H), 3.88-3.78 (m, 2H), 3.64 (m, 1H), 3.47 (m, 1H), 3.20 (, 1H), 2.03 (m, 1H), 1.84 (m, 1H), 0.86 (s, 9H), 0.016 (s, 6H); MS APCI, m / z = 557 (M +). (c) N- [2- (S) - (3,4-dichlorophenyl) -4-tert-butyldimethylsilyloxybutyl] -3-cyano-2-hydroxy-1-naphthamide. A 250 mL 3-necked flask containing a magnetic stirrer and magnesium chips (0.68 g, 27.96 mmol) was dried to the flame and allowed to cool to room temperature under nitrogen. After adding diethyl ether (30 mL), benzene (15 mL) and iodine (3.55 g, 13.98 mmol), the reaction mixture was heated under reflux for 2 h. After cooling, the solution was transferred via cannula to a flask containing N- [2- (S) - (3,4-dichlorophenyl) -4-tert-butyldimethylsilyloxybutyl] -3-cyano-2-methoxy-1-naphthamide (6.48 g, 11.65 mmol) in 108 mL of benzene. Heating was continued under reflux for 1 h, then cooled to room temperature. IN of HCl and DCM were introduced and allowed to stir for 15 min. The mixture was washed twice with water, dried over Na 2 SO 4, filtered, and concentrated to give a quantitative production of a light yellow solid. 1H NMR (300 MHz, CDCl 3) d 11.91 (bs, 1H), 8.15 (s, 1H), 7.77 (m, 1H), 7.45-7.13 (m, 6H), 6.28 (, 1H), 3.96 (m, 1H), 3.62-3.25 (m, 4H), 1.99 (m, 1H), 1.84 (, 1H), 0.70 (s, 9H), .011 (s, 6H); MS APCI, m / z = 543 (M +). (d) N- [2- (S) - (3,4-dichlorophenyl) -4-tert-butyldimethylsilyloxybutyl] -3-cyano-2-methanesulfonyloxy-1-naphthamide. Using typical conditions, N- [2- (S) - (3,4-dichlorophenyl) -4-tert-butyldimethylsilyloxybutyl] -3-cyano-2-hydroxy-1-naphthamide (2.40 g, 4.42 mmol) was reacted with methanesulfonyl chloride (0.51 g, 4.95 mmol) and triethylamine (1.13 g) in DCM, then purified by chromatography (eluting with 40% hexane / Et20) to give the product (1.82 g, 67% yield) as a solid white. ? E NMR (300 MHz, CDCl3) d 8.29 (s, 1H), 7.92 (m, 1H), 7.69 (m, 2H), 7.47-7.4 (m, 3H), 7.20 (dd, 1H), 6.27 (t , 1H), 3.88 (m, 1H), 3.80 (m, 1H), 3.63 (m, 1H), 3.54 (s, 3H), 3.47 (m, 1H), 3.20 (m, 1H), 2.0 (m, 1H), 1.83 (m, 1H), 0.87 (s, 9H), 0.028 (s, 6H); MS APCI, m / z = 621 (M +). (e) N- [2- (S) - (3,4-dichlorophenyl) -4-hydroxybutyl] -3-cyano-2-methanesulfonyl? i-1-naphthamide. In a round bottom flask containing 5% HF in CH3CN (composed of 44.2 mL 49% aqueous HF and 397.6 mL CH3CN) was added a solution of N- [2- (S) - (3, 4- dichlorophenyl) -4-tert-butyldimethylsilyloxybutyl] -3-cyano-2-methanesulfonyloxy-1-naphthamide (2.74 g, 4.42 mmol) in 40 mL of CH3CN. After stirring at room temperature for 4 h, the reaction was quenched by the addition of DCM, water, then NaHCO3 was added to adjust to pH 7. The organic layer was collected, washed twice with water, dried, filtered , and concentrated. The material was purified by chromatography (0.5-2.0% MeOH in DCM) to give the product (2.14 g, 96% yield) as a white solid. ? E NMR (300 MHz, CDC13) d 8.25 (s, 1H), 7.89 (m, 1H), 7.64 (m, 2H), 7.39 (m, 3H), 7.23 (dd, 1H), 6.37 (s, 1H) ), 3.82 (t, 2H), 3.65 (m, 1H), 3.51 (s, 3H), 3.46 (m, 1H), 3.15 (m, 1H), 2.04 (m, 1H), 1.86 (m, 1H) , 1.64 (m, 1H); MS APCI, m / z = 507 (M +). (f) N- [2- (S) - (3,4-dichlorophenyl) -4-oxobutyl] -3-cyano-2-ethylsulphonyloxy-1-naphthamide. N- [2- (S) - (3,4-dichlorophenyl) -4-hydroxybutyl] -3-cyano-2-methanesulfonyloxy-1-naphthamide was reacted with oxalyl chloride and DMSO under standard Swern oxidation conditions in DCM. After aqueous extraction of DCM, and gradient chromatography (1%, 20%, and 50% Et20 in DCM) the product (24% yield) was given as a white solid. XH NMR (300 MHz, CDC13) d 8.35 (m, 1H), 7.99 (m, 2H), 7.82-7.69 (m, 3H), 7.42 (m, 1H), 7.24 (m, 1H), 6.19 (m, 1H), 3.83 (m, 2H), 3.59 (s, 3H), 3.44 (m, 1H), 2.34-2.16 (m, 2H); MS APCI, m / z = 505 (M +).

Example 27 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [2- (methoxy-1,2-dioxoethylamino) phenyl] -1-piperidinyl] butyl] citrate methyl-3-cyano-2-methoxy-1-naphtamide.

The N- [2- (S) - (3,4-dichlorophenyl) -4-oxobutyl] -N-methyl-3-cyano-2-methoxy-1-naphthamide was reacted with 4- (2- ( methoxy-1,2-dioxoethylamino) phenyl) piperidine under standard reductive amination conditions. The product was converted to the citrate salt and recovered as a white powder. 1 H NMR (300 MHz, DMSO-d 6) d 8.62 (m), 8.04 (m), 7.80-6.83 (m), 6.33 (m), 4.52 (m), 3.95 (s), 3.85 (s), 3.33 (m), 3.20-2.60 (m), 2.65-2.40 (m), 2.30-1.65 (m); MS APCI, m / z = 701 (M + H). The required 4- (2- (methoxy-1,2-dioxoethylamino) phenyl) piperidine hydrochloride was prepared as follows. (a) 4- (2-Aminophenyl) piperidine. 4- (2-nitrophenyl) piperidine hydrochloride (prepared by the Ullmann coupling of 2-nitrobromobenzene and 4-bromopyridine according to the method of Shimizu, N.; Kitamura, T .; Watanabe, K.; Yamaguchi, T .; Shigyo, H .; Ohta, T .; Tetrahedron Letters 34 1993, 3421) (6.90 g) was dissolved in acetic acid (100 mL), platinum dioxide (1.60 g) was added and the mixture was hydrogenated on a Parr-shaker at 50 psi hydrogen pressure during 4 h. The solution was filtered and evaporated to give the title compound as a yellow oil which was used directly in the next reaction. MS APCI, m / z = 177 (M + H). (b) tert-Butyl 4- (2-aminophenyl) piperidine-1-carboxylate.

A solution of 4- (2-aminophenyl) piperidine (4.04 g) in water (200 mL) was adjusted to pH 9 by the addition of potassium carbonate and cooled in an ice water bath. A solution of di-tert-butyl bicarbonate (5.20 g) in 1,4-dioxane (80 L) was added dropwise. The stirred mixture was allowed to warm gradually at room temperature for 3 h. Additional potassium carbonate was added as necessary to maintain the pH 9. The reaction was extracted with ethyl ether. The organic extracts were dried and evaporated. The residue was purified by chromatography, with 3: 1 hexanes: EtOAc as the eluent, to give the title compound (3.26 g). H NMR (300 MHz, DMS-de) d 6.87 (m, 2H), 6.65 (d, 1H), 6.52 (m, 1H), 4.91 (s, 2H, NH2), 4.04 (m, 2H), 2.76 ( m, 3H), 1.70 (m, 2H), 1.42 (s, 9H), 1.34 (m, 2H); MS APCI, m / z = 177 (M-Boc), 299 (M + Na). (c) tert-Butyl 4- (2- (methoxy-1,2-dioxoethylamino) phenyl) piperidine-1-carboxylate. Methylloxalilchloride (0.094 g) was added to a solution of tert-butyl 4- (2-aminophenyl) piperidine-1-carboxylate (0.172 g) and triethylamine (0.073 g) in DCM (4 mL) and stirred overnight to dilute after in IN of aqueous hydrogen chloride. The organic phase was dried and evaporated to give the title compound (0.207 g) as an oil. MS APCI, m / z = 362 (M + H). ? E NMR (CDC13) d 7.83 (m, 1H), 7.21 (m, 3H), 6.30 (br, 1H, NH), 4.24 (m, 2H), 3.72 (s, 3H, OCH3), 2.77 (m, 3H), 1.67 (m, 4H), 1.51 (s, 9H). (d) 4- (2- (methoxy-1,2-dioxoethylamino) phenyl) piperidine hydrochloride. The hydrogen chloride gas was delicately bubbled through a solution of EtOAc (8 L) containing tert-butyl 4- (2- (methoxy-1,2-dioxoethylamino) phenyl) piperidine-1-carboxylate (0.140) g) at 0 ° C for 5 min. The reaction solution was evaporated to give the title compound as a white solid which was used directly in the next reaction.

Example 28 N- [2- (S) - (3,4-dichlorophenyl) -4- [4- [2- (N, N-dimethylaminocarbonylamino) enyl] -1-piperidinyl] butyl] -3-cyano- citrate 2-methoxy-1-naph amide.

The N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-N-methyl-3-cyano-2-methoxy-1-naphthamide was reacted with 4- [2- ( N, N-dimethylaminocarbonylamino) phenyl] -piperidine under standard reductive amination conditions. The product was converted to the citrate salt and recovered as a white powder. ? E NMR (300 MHz, DMSO-d6) d 8.64 (m), 8.02 (m), 7.87-7.19 (), 6.33 (m), 4.53 (), 3.95 (s), 3.33 (m), 2.92 (m ), 2.65-2.49 (m), 1.85 (m), 1.75 (m); MS APCI, m / z = 686 (M + H). The required 4- [2- (N, N-dimethylaminocarbonylamino) phenyl] -piperidine hydrochloride was prepared as follows. (a) tert-Butyl 4- [2- (N, N-dimethylaminocarbonylamino) phenyl)] piperidine-1-carboxylate. Triphosgene (0.305 g) was added to a solution of tert-butyl 4- (2-aminophenyl) -piperidine-1-carboxylate (Example 27) (0.260 g) in DCM (25 mL). Triethylamine (0.115 g) was added rapidly with vigorous stirring. After 15 min 2M dimethylamine in THF (5 mL) was added and the mixture was stirred for 1 h. The reaction was diluted with IN of HCl and extracted with DCM. The organic extracts were dried and evaporated to give the title compound (0.415 g) as a colorless oil. MS APCI, m / z = 248 (M-Boc); XH NMR (300 MHz, CDC13) d 7.28 (m, 5H), 6.00 (s, 1H), 4.44 (m, 1H), 4.23 (br, 1H), 3.75 (m, 1H), 3.00 (m, 1H), 3.06 (s, 6H), 1.85 (m, 1H), 1.69 (m, 3H), 1.48 (s, 9H). (b) 4- [2- (N, N-dimethylaminocarbonylamino) phenyl] -piperidine hydrochloride. The hydrogen chloride gas was delicately bubbled through a solution of EtOAc (10 mL) containing tert Butyl 4- [2- (N, -dimethylaminocarbonylamino) phenyl)] piperidine-l-carboxylate (0.297 g) a 0 ° C for 5 min. The reaction solution was evaporated to give the title compound as a white solid (0.240 g). MS APCI, m / z = 246 (M + H).

EXAMPLE 29 Trifluoroacetate N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [2- (N-oxo-N, N-dimethylamino) phenyl] -1-piperidinyl] butyl] -N -methyl-3-cyano-2-me oxy-1-naphtamide.

Using standard reductive amination conditions, 4- (2- (N-oxo-N, N-dimethylamino) phenylpiperidine was reacted with N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl -N-methyl-3-cyano-2-methoxy-1-naphtamide, the product was purified by preparative HPLC and recovered as the trifluoroacetate salt.XH NMR (300 MHz, CDC13) d 8.30-8.10 (m), 8.00 -7.00 (m), 6.95-6.55 (m), 4.45-4.10 (m), 4.09 (s), 4.02 (s), 3.96 (m), 3.91 (s), 3.72 (), 3.50-2.75 (m) , 2.58 (s), 2.54 (s), 2.50-1.90 (m); MS APCI, m / z = 659 (M + H) .The 4- (2- (N-oxo-N, -dimethylamino) phenyl) The required piperidine was prepared as follows: (a) Tert-Butyl 4- [2-N, N-dimethylaminophenyl] piperidine carboxylate Formaldehyde (37 weight% in water) was added to a solution of tert-butyl 4- (2) -aminophenyl) piperidine-l-carboxylate (Example 27, step (b)) (0.065 g) in methanol (2 mL). Acetic acid (0.01 mL) was added, the mixture was stirred 5 min then sodium cyanoborohydride ( 0.100 g) in me tanol (2 mL) After 2 h, the solvent was evaporated and the residue was partitioned between ethyl ether and aqueous sodium bicarbonate. The organic phase was dried and evaporated to give the title compound (0.071 g) as a waxy solid. MS: m / z = 305 (M + H). XE NMR (CDC13) d 7.26 (m, 4H), 3.34 (m, 1H), 2.84 (m, 2H), 2.62 (s, 6H, N-CH3), 1.62 (m, 6H), 1.54 (s, 9H). (b) 4- (2- (N-oxo-N, N-dimethylamino) phenyl) piperidine. 3-Chloroperoxybenzoic acid (0.125 g) in DCM was added (2 mL) was added to tert-butyl 4- [2-N, N-dimethylaminophenyl] piperidine-l-carboxylate (0.220 g) in DCM (10 mL) and stirred for 1 h. The reaction mixture was extracted sequentially with aqueous sodium sulfite and aqueous sodium bicarbonate. The organic phase was dried and evaporated to give tert-butyl 4- [2- (N-oxo-N, N-dimethylamino) phenyl] piperidine-1-carboxylate (0.206 g) as a white foamy solid. MS: m / z = 321 (M + H). This material was N-deprotected with HCl (according to the procedure of Example 27) to achieve 4- [2- (N-oxo-N, N-dimethylamino) phenyl] piperidine hydrochloride which was used without purification.

EXAMPLE 30 N- [2- (S) - (3,4-Dichlorophenyl) -4- [4- [2-methylsulfinyl-4-methoxycarbonylphenyl] -1-piperidinyl] butyl] -N-methyl-2-methoxy citrate -3-cyano-l-naphtamide.

Using standard reductive amination conditions N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-N-methyl-2-methoxy-3-cyano-l-naphthamide (0.160 g) was made react with 4- [2-methylsulfinyl-4-methoxycarbonylphenyl] piperidine (0.093 g) and converted to the citrate salt. MS m / z 720 (M +); XH NMR (DMSO-de) d 8.77-8.55 (m), 8.20-6.70 (m), 6.34 (d), 4.53 (t), 4.10-3.65 (m), 3.60-3.00 (m), 2.90-2.30 ( m), 2.20-1.60 (m). The required 4- [2-methylsulfinyl-4-methoxycarbonylphenyl] piperidine was prepared as follows. (a) 4- [2-methylsulfinyl-4-bromophenyl] piperidine. To a stirred solution of 4- (2-methylsulfinylphenyl) piperidine (Jacobs, R; Shenvi, A; EP 630887) (0.496 g) dissolved in 5 mL of acetic acid was added a solution of bromine (0.715 g in 15 mL of acetic acid.The mixture was heated to 75 ° C for 80 min. mL of water, the solvent was evaporated, and the residue was dissolved in water.The aqueous mixture was basified to pH 14 by the addition of KOH and extracted with CHC1 (3 x 15 mL) .The organic extracts were combined, dried Na2SO4, evaporated and purified by chromatography (19: 1 DCM: methanol containing 0.5% aqueous NHOH) to achieve the product (0.421 g) as a light yellow solid. MS m / z 302 (M + H). -? NMR (CDCl 3) d 7.86 (d, 1H), 7.61 (dd, 1H), 7.52 (d, 1H), 3.25-3.35 (, 2H), 3.08-2.60 (m, 7H), 2.04-1.61 (m, 4H ). (b) 4- [2-methylsulfinyl-4-methoxycarbonylphenyl] piperidine. 4- [2-Methylsulfinyl-4-bromophenyl] piperidine was N-protected using di (tert-butyl) dicarbonate in dioxane solvent using aqueous NaOH as the base, then isolated by extraction. A solution of the resulting N-Boc-4- [2-methylsulfinyl-4-bromophenyl] piperidine (1.17 g), was dissolved in 1: 1 methanol: DMSO (50 mL) with triethylamine (0.39 g), palladium acetate (0.092 g), and 1,3-bis (diphenylphosphino) propane (0.184 g), was stirred at 70 ° C under carbon monoxide (1 atm) for 16 h. The mixture was cooled, diluted with EtOAc, and the organic layer was washed with water, dried, and purified by chromatography to achieve N-Boc-4- [2-methylsulfinyl-4-methoxycarbonylphenyl] piperidine (0.52 g). XH NMR (CDC13) d 8.15-8.05 (m, 2H), 7.99-7.95 (m, 1H), 4.40-4.15 (m, 2H), 3.95 (s, 3H), 2.95-2.65 (m, 3H), 2.73 (s, 3H), 1.95-1.45 (m, 4H), 1.50 (s, 9H). The N-deprotection of 4- [2-methylsulfinyl-4-methoxycarbonylphenyl] piperidine was carried out using TFA under standard conditions to give 4- [2-methylsulfinyl-4-methoxycarbonylphenyl] piperidine. XH NMR (CDC13) d 8.15-8.03 (m, 3H), 3.94 (s, 3H), 3.30-3.15 (m, 2H), 2.90-2.65 (m, 4H), 2.72 (s, 3H), 1.95-1.50 (m, 4H); MS m / z 282 (M + H).

EXAMPLE 31 N- [2- (S) - (3,4-Dichlorophenyl) -4- [4- [2-methylsulfinyl-4-aminophenyl] -1-piperidinyl] butyl] -N-methyl-2-ethoxy citrate -3-cyano-l-naphtamide.

Using standard reductive amination conditions the N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-N-methyl-3-cyano-2-methoxy-1-naphthamide (0.091 g) was made react with 4- [2-methylsulfinyl-4-aminophenyl] -piperidine (0.048 g) and converted to the citrate salt. MS m / z 677 (M +); XH NMR (DMSO d6) d 8.75-8.55 (m), 8.20-7.25 (m), 7.15-6.00 (m), 4.51 (t), 4.10-3.20 (m), 3.18-2.30 (m), 2.15-1.60 (). The required 4- [2-methylsulfinyl-4-aminophenyl] -piperidine was prepared as follows.

Reaction scheme B (a) 4- [4-Methoxy-2-methylthiophenyl] piperidine. The N-deprotection of l-Cbz-4- [4-methoxy-2-methylthiophenyl] piperidine (Example 7, step f) was completed by stirring in TFA for 1 h at 80 ° C. The mixture was neutralized by the addition of KOH, then extracted into chloroform to achieve the product. ? E NMR (CDC13) d 7.15 (d, 1H), 6.76 (d, 1H), 6.69 (dd, 1H), 3.80 (s, 3H), 3.18 (dm, 2H), 3.01 (tt, 1H), 2.78 (td, 2H), 2.45 (s, 3H), 1.82 (m, 2H), 1.66 (s, 1H), 1.58 (qd, 2H); MS m / z 238 (M + H). (b) 4- [4-Hydroxy-2-methylthiophenyl] piperidine hydrobromide. A mixture of pyridinium hydrobromide (20.76 g) and 4- [4-methoxy-2-methylthiophenyl] piperidine (6.16 g) was heated at 225 ° C for 18 h. The reaction mixture was cooled, dissolved in 200 mL of water, adjusted to pH 7 with IN of KOH, and extracted with hexane. The aqueous layer was concentrated under reduced pressure to give an oil which was dissolved in 200 mL of EtOH and stirred for 0.5 h. The precipitate was filtered and washed with EtOH. The combined EtOH filtrates were concentrated under reduced pressure and purified by chromatography (9: 1 DCM: MeOH) to give 6.06 g of the product. XH NMR (DMSO d6) d 9.44 (s, 1H), 8.49 (m, 2H), 6.97 (d, 1H), 6.66 (d, 1H), 6.58 (dd, 1H), 3.43-3.30 (dm, 2H) , 3.13-2.95 (m, 3H), 2.42 (s, 3H), 1.91-1.61 (m, 4H); MS m / z 225 (M + H). (c) l-Cbz-4- [4-Hydroxy-2-methylthiophenyl] piperidine. To a rapidly stirred slurry of 4- [4-hydroxy-2-methylthiophenyl] piperidine hydrobromide (2.57 g) and triethylamine (4.00 mL) in 200 mL of THF was slowly added 2.50 L of chloroformate benzyl for 10 minutes. Aqueous NaHCO3 was added, the THF was removed under reduced pressure, the residue was dissolved in DCM, washed with aqueous NaHC 3, concentrated to an oil, and re-dissolved in 160 L of 1: 1 THF: water. To this was added 0.26 g of LiOH and the mixture was stirred for 18 h. THF was evaporated under reduced pressureThe aqueous residue was acidified with 15 mL of IN HCl, and extracted with DCM, dried, and concentrated under reduced pressure to give an oil which was purified by chromatography (2: 3 EtOAc: hexane) to give 1.71 g of solid product. XH NMR (CDC13) d 7.45-7.25 (m, 5H), 6.99 (d, 1H), 6.70 (d, 1H), 6.59 (dd, 1H), 5.16 (s, 2H), 5.03 (s, 1H), 4.41-4.25 (m, 2H), 3.04 (tt, 1H), 3.00-2.83 (m, 2H), 2.44 (s, 3H), 1.90-1.45 (m, 4H); MS m / z 358 (M + H). (d) l-Cbz-4- [4-aminocarbonyl (dimethyl) methyloxy) -2-methylthiophenyl] piperidine. The l-Cbz-4- [4-hydroxy-2-methylthiophenyl] piperidine (0.951 g) was reacted with NaH (0.160 g 60% dispersion of mineral oil) in dioxane solvent (15 mL) at room temperature for 2 hours. h. This was treated with 2-bromo-2-methylpropanamide (Coutts and Southcott; J. Chem. Soc., Perkin Trans. 1, 1990, 767) (0.662) and heated at 100 ° C for 2 h. The mixture was emptied into 30 mL of saturated NaHCO 3 and extracted with DCM, dried, and concentrated under reduced pressure to give an oil which was purified by chromatography (40: 1 DCM: MeOH) to obtain 0.835 g of solid product XH NMR (CDC13) d 7.45-7.25 (m, 5H), 7.03 (d, 1H), 6.78 (d, 1H), 6.70 (dd, 1H), 6.60 (m, 1H), 5.62 (m, 1H), 5.16 (s, 2H), 4.43-4.21 (m, 2H), 3.06 (tt, 1H), 3.00- 2.87 (m, 2H), 2.44 (s, 3H), 1.90-1.45 (m, 4H) 1.54 (s, 6H); MS m / z 443 (M + H). (e) 4- [4- (2-hydroxy-2-methylpropionamido) -2-methylthiophenyl] -N-Cbz-piperidine. 4- [4-aminocarbonyl (dimethyl) methyloxy) -2-methylthiophenyl] -N-Cbz-piperidine (0.835 g) was reacted with NaH (0.106 g 60% dispersion of mineral oil) in 10 mL of DMF containing 1.0 mL of 1,3-dimethyl-3,4,6,6-tetrahydro-2 (1H) -pyrimidone and was heated at 100 ° C for 2 h. The mixture was emptied into 50 mL of water and extracted with 1: 1 EtOAc: Et20, washed with water, dried, and concentrated under reduced pressure to give an oil which was purified by chromatography (40: 1 DCM: MeOH) to give 0.491 g of solid product; H NMR (CDC13) d 8.65 (m, 1H), 7.70 (d, 1H), 7.45-7.25 (, 5H), 7.17 (dd, 1H), 7.09 (d, 1H), 5.16 (s, 2H), 4.43 -4.21 (m, 2H), 3.09 (tt, 1H), 3.03-2.87 (m, 2H), 2.50 (s, 3H), 1.90-1.45 (, 4H), 1.56 (s, 3H), 1.56 (s, 3H); MS m / z 443 (M + H). (f) 4- [4- (2-Hydroxy-2-methylpropionamido) -2-methylsulfinylphenyl] -N-Cbz-piperidine. To a stirred solution of NaI04 (1.56 g) in 100 mL of 1: 1 THF: water was added 4- [4- (2-hydroxy-2-methylpropionamido) -2-methylthiophenyl] -N-Cbz-piperidine (0.65 g). g). After 18 h, the THF was removed under reduced pressure, and the residue was diluted with 60 mL of saturated NaHCO 3 and extracted with DCM, dried and evaporated to give 0.585 g of an oil after chromatography (20: 1). DCM: MeOH). X H NMR (CDCl 3) d 8.92 (m, 1 H), 8.05 (dd, 1 H), 7.84 (d, 1 H), 7.45-7.25 (m, 5 H), 7.26 (d, 1 H), 5.16 (s, 2 H), 4.43-4.22 (m, 2H), 2.97-2.78 (m, 3H), 2.71 (s, 3H), 1.90-1.45 (m, 4H), 1.57 (s, 3H), 1.55 (s, 3H); MS m / z 459 (M + H). (g) 4- [4-Amino-2-methylsulfinylphenyl] piperidine. To a solution of KOH (0.72 g) in 40 mL of 1: 1 EtOH: water was added 0.585 g of 4- [4- (2-hydroxy-2-methylpropionamido) -2-methylsulfinylphenyl] -N-Cbz-piperidine. .

The resulting mixture was refluxed under nitrogen for 36 h, evaporated, dissolved in 10 mL of water, and extracted with CHC13, dried, filtered, and concentrated under reduced pressure. The resulting residue was purified by chromatography (9: 1, DCM: MeOH with 2% aqueous NHOH) to give 0.148 g of white solid. The purified product was a 2: 3 mixture of 4- [4-amino-2-methylsulfinylphenyl] piperidine and 4- [4- (2-hydroxy-2-methylpropionamido) -2-methylsulfinylphenyl] -piperidine, as determined by 1H NMR. This mixture was used directly in the subsequent reaction. XH NMR (CDCI3) d 8.67 (m), 8.06 (dd), 7.82 (d), 7.35 (d), 7.13 (d, 1H), 6.76 (dd), 3.82 (m), 3.30-3.10 (m), 2.90- 2.60 (m), 2.71 (s), 2.67 (s), 1.90-1.45 (m); MS m / z 239 (M + H).

Example 32 N- [(S) -2- (3,4-dichlorophenyl) -4- [5-methoxy-2-methylsulinylphenyl] -1-piperidinyl] util] -N-methyl-3-cyano-2 citrate -methoxy-1-naphtamide.

Using standard reductive amination conditions the N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-N-methyl-3-cyano-2-methoxy-1-naphthamide (0.242 g) was made react with 4- [5-methoxy-2-methylsulfinylphenyl] -1-piperidine (0.134 g) and converted to the citrate salt. MS: m / z 692 (M +); X NMR (DMSO-de) d 8.75-8.60 (m), 8.20-6.70 (m), 6.33 (d), 4.54 (t), 4.10-3.60 (m), 3.55-3.00 (m), 2.98-2.30 (m), 2.20-1.60 (m). The required 4- [5-methoxy-2-methylsulfinylphenyl] -1-piperidine was prepared according to the procedures described in Example 7 except that 4-methoxyphenol was used in place of 3-methoxyphenol; therefore, the 4-methoxyphenol (11.38 g) was reacted with bromine (14.89 g) to give 18.54 g of crude 2-bromo-4-methoxyphenol. 1 H NMR (CDC13) d 7.01 (d, 1 H), 6.94 (d, 1 H), 6.80 (dd, 1 H), 5.14 (s, 1 H), 3.75 (s, 3 H). The analytical data for all other intermediaries is as follows. 2-Bromo-4-methoxy- (N, N-dimethylthiocarbamoyl) phenol; ? E NMR (CDC13) d 7.12 (d, 1H), 7.05 (d, 1H), 6.85 (dd, 1H), 3.80 (s, 3H), 3.47 (s, 3H), 3.36 (s, 3H); MS m / z 290 (M +). 5-Methoxy-2- (N, N-dimethylthiocarbamoyl) bromobenzene; 1 H NMR (CDCl 3) d 7.50 (d, 2 H), 7.24 (d, 1 H), 6.87 (dd, 1 H), 3.81 (s, 3 H), 3.20-1.92 (m, 6 H); MS m / z 290 (M +). 5-Methoxy-2- (methylthio) bromobenzene; XE NMR (CDCl 3) d 7.19 (d, 1H), 7.15 (d, 1H), 6.87 (dd, 1H), 3.79 (s, 3H), 2.45 (s, 3H). 4-Hydroxy-4- (5-methoxy-2-methylthio-phenyl) -l-N-Cbz-piperidine; XH NMR (CDC13) d 7.43 (d, 1H), 7.43-7.25 (m, 5H), 6.89 (d, 1H), 6.80 (dd, 1H), . 15 (s, 2H), 4.25-4.00 (m, 2H), 3.80 (s, 1H), 3.50-3.25 (m, 2H), 2.47 (s, 3H), 2.15-1.90 (m, 4H); MS m / z 370 (M-H20). 4- (5-Methoxy-2-methylthiophenyl) -1-N-Cbz-piperidine; XH NMR (CDCl 3) d 7.50-7.28 (m, 6H), 6.80-6.65 (m, 2H), 5.14 (s, 2H), 4.42-4.20 (m, 2H), 3.79 (s, 3H), 3.28 (tt) , 1H), 3.00-2.90 (m, 2H), 2.40 (s, 3H), 2.05-1.50 (m, 4H); MS m / z 372 (M + H). 4- (5-Methoxy-2-methylsulfinylphenyl) -1-N-Cbz-piperidine; XK NMR (CDCl 3) d 7.91 (d, 1H), 7.42-7.30 (m, 5H), 6.98 (dd, 1H), 6.76 (d, 1H), 5.16 (s, 2H), 4.45-4.22 (m, 2H) ), 3.84 (s, 3H), 3.03 (tt, 1H), 3.00-2.85 (m, 2H), 2.69 (s, 3H), 1.98-1.55 (m, 4H); MS m / z 388 (M + H). 4- (5-Metsxy-2-methylsulfinylphenyl) -piperidine; ? E NMR (CDC13) d 7.91 (d, 1H), 6.97 (dd, 1H), 6.87 (d, 1H), 3.84 (s, 3H), 3.28-3.12 (m, 2H), 2.92 (tt, 3H), 2.74 (td, 1H), 2.68 (s, 3H), 1.88 (dm, 2H), 1.76 (qd, 2H); MS m / z 254 (M + H).

Example 33 N- [(S) -2- (3,4-dichlorophenyl) -4- [4-methoxy-2-methylsulfinylphenyl] -l-piperidinyl] butyl] -N-methyl-3-cyano-2- citrate methylsulfonyl-1-naphtamide.

Using standard reductive amination conditions the N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-N-methyl-3-cyano-2-methylsulfonyl-1-naphthamide (0.255 g) was made react with 4- [4-methoxy-2-methylsulfinylphenyl] -1-piperidine (0.132 g) and converted to the citrate salt. MS: m / z 740 (M +); ? E NMR (DMSO-de) d 9.00-8.82 (m), 8.32-6.80 (m), 6.47 (d), 4.66 (t), 4.20-3.00 (m), 2.95-2.21 (m), 2.20-1.60 (m); Analysis for C3-.H39Cl2N3? 5S2 »l .0 citric acid» 1.0 H20: calculated; C, 54.31; H, 5.19; N, 4.42; found; C, 54.03; H, 5.05; N, 4.36. The required N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-N-methyl-3-cyano-2-methylsulfonyl-1-naphthamide was prepared as follows. (a) Methyl 3-cyano-2-methylthio-l-naphthoate. The methyl-3-cyano-2-trifluoromethanesulfonyloxy-1-naphthoate (6.25 g) was reacted with sodium thiomethoxide (2.46 g) in toluene according to the method of Zheng; J. Org. Chem., 1998, 63, 9606, except that the stoichiometric amounts used of Pd (OAc) (0.42 g) and (S) - (-) - 2, 2'-bis (diphenylphosphino) -1, 1'-biphenyl ( 1.25 g) were used here. The mixture was heated at 100 ° C for 66 h, diluted with 200 L of EtOAc and 100 mL of DCM, extracted with 20% K2C03, and saline, dried, and concentrated under reduced pressure to give an oil which was purified by chromatography (DCM) to give 3.40 g of solid product. ? E NMR (CDC13) d 8.33 (s, 1H), 7.92 (m, 1H), 7.78-7.60 (m, 3H), 4.09 (s, 3H), 2.58 (s, 3H). (b) 3-Cyano-2-methylthio-l-naphthoic acid Methyl 3-cyano-2-methylthio-l-naphthoate (3.20 g) was stirred with 20 g of trimethylsilyl iodide and heated at 70 ° C for 2 hours. h. The reaction was stopped by the slow addition of 20 mL of water, diluted with 300 mL of DCM and extracted with 150 mL of 5% NaHSO. The organic layer was dried and concentrated under reduced pressure to give a yellow solid. ? E NMR (CDC13) d 8.38 (s, 1H), 7.96 (m, 2H), 7.78 (m, 2H), 7.70 (m, 2H), 2.64 (s, 3H). (c) N- [2- (S) - (3,4-Dichlorophenyl)] -4-hydroxybutyl-N-methyl-3-cyano-2-methylthio-1-naphthamide. 3-Cyano-2-methylthio-l-naphthoyl chloride (2.36 g) (prepared from 3-cyano-2-methylthio-l-naphthoic acid using oxalyl chloride under standard conditions) was combined with N- [2- (S) - (3,4-dichlorophenyl) -4-hydroxybutyl] -N- methylamine (2.58 g) and triethylamine under standard acylation conditions to achieve the product (4.24 g) as a solid after purification by chromatography (4: 1 Et0Ac: DCM); MS: m / z 473 (M +); XH NMR (CDC13) d 8.45-8.20 (m), 8.00-7.20 (m), 7.05-6.40 (m), 4.47 (m), 4.20-3.05 (m), 2.70-2.22 (m), 2.18-1.40 ( m). (d) N- [2- (S) - (3,4-Dichlorophenyl)] -4-hydroxybutyl-N-methyl-3-cyano-2-methylsulfonyl-1-naphthamide. To a solution of N- [2- (S) - (3,4-dichlorophenyl)] -4-hydroxybutyl-N-methyl-3-cyano-2-methylthio-l-naphthamide (0.804 g) in 50 mL of HOAC 3.2 mL of 30% H202 was added. The mixture was heated at 50 ° C for 5 h, the HOAC was evaporated under reduced pressure, the residue was slowly mixed with 30 mL of saturated NaHCO3, extracted with DCM, dried, and concentrated under reduced pressure to give a solid (0.604 g) after purification by chromatography (40: 1 DCM: MeOH); MS: m / z 505 (M +); E NMR (CDC13) d 8.55-8.38 (m), 8.10-7.10 (m), 7.00-6.50 (m), 4.69 (dd), 4.20 (dd), 3.81-3.15 (m), 2.75-2.55 (m) , 2.22-1.40 (m). (e) N- [2- (S) - (3,4-Dichlorophenyl)] -4-oxobutyl-N-methyl-3-cyano-2-methylsulfonyl-1-naphthamide. The N- [2- (S) - (3,4-dichlorophenyl)] -4-hydroxybutyl-N-methyl-3-cyano-2-methylsulfonyl-1-naphthamide (0.604 g) was reacted with oxalyl chloride and DMSO under standard Swern oxidation conditions in DCM (35 mL) to achieve the product (0.512 g) as a solid after extraction with DCM and purification by chromatography (1: 1 DCM: EtOAc); MS: m / z 503 (M +); XH NMR (CDC13) d 9.77 (s), 8.55-8.38 (m), 8.10-7.10 (m), 7.00-6.55 (m), 4.67 (dd), 4.20-4.00 (m), 3.85-3.55 (m) , 2.70 (s), 2.60 (s), 3.40-2.40 (m).Example 34 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [4-chloro-2-methylsulfinylphenyl] -1-piperidinyl] util] -N-methyl-3-cyano citrate -2-methoxy-1-naphtamide.

Using standard reductive amination conditions N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-N-methyl-3-cyano-2-methoxy-1-naphtamide (0.310 g) was made react with 4- [4-chloro-2-methylsulfinylphenyl] -1-piperidine (0.179 g) to achieve the product as a white powder (0.245 g) and converted to the citrate salt. MS: m / z 696 (M +); 1 H NMR (DMSO-de) d 8.75-8.60 (m), 8.15-7.92 (m), 7.82-6.75 (m), 6.32 (d), 4.53 (t), 4.15-3.65 (m), 3.60-2.91 ( m), 2.90-2.30 (m), 2.20-1.50 (m); analysis for C36H36C13N303S «1.0 citric acid-1.0 H20: calculated; C, 55.60; H, 5.11; N, 4.63; found; C, 55.82; H, 5.00; N, 4.75. The required 4- (4-chloro-2- (R, S) -methylsulfinylphenyl) piperidine was prepared according to the procedures described in Example 7 except that 3-chlorophenol was used in place of 3-methoxyphenol. Oxidation of the methylthio adduction was carried out according to the procedure described in Example 31 (f). 3-Chlorophenol (24.28 g) was reacted with bromine (29.78 g) to give 6.15 g of 2-bromo-5-chlorophenol (minor isomer) and 24.60 g of 4-bromo-3-chlorophenol (major isomer) after purification by column chromatography (10: 1 hexane: EtOAc); minor isomer- XH NMR (CDC13) d 7.37 (d, 1H), 7.04 (d, 1H), 6.82 (dd, 1H), 5.55 (s, 1H). Major isomer:? NMR (CDC13) d 7.36 (d, 1H), 6.91 (d, 1H), 6.57 (dd, 1H), 5.75 (s, 1H). The data analyzed for all other intermediaries are as follows. 2-Bromo-5-chloro- (N, N-dimethylthiocarbamoyl) phenol; ? E NMR (CDCl 3) d 7.52 (d, 1H), 7.18 (d, 1H), 7.13 (dd, 1H), 3.47 (s, 3H), 3.39 (s, 3H); MS m / z 296 (M +). 4-Chloro-2- (N, N-dimethylthiocarbamoyl) -bromobenzene; 1 H NMR (CDCl 3) d 7.68- 7.55 (m, 2 H), 7.23 (dd, 1 H), 3.12 (s, 3 H), 3.05 (s, 3 H); MS m / z 296 (M +). 4-Chloro-2- (thiomethyl) bromobenzene; - "" H NMR (CDCl 3) d 7.43 (d, 1H), 7.06 (d, 1H), 6.97 (dd, 1H), 2.48 (s, 3H). l-Benzyloxycarbonyl-4-hydroxy-4- (4-chloro-2-methylthiophenyl) piperidine; ? E NMR (CDC13) d 7.43-7.30 (m, 6H), 7.26 (d, 1H), 7.15 (dd, 1H), 5.15 (s, 2H), 4.25-4.00 (m, 2H), 3.84 (s, 1H), 3.50-3.25 (m, 2H), 2.52 (s, 3H), 2. 15-1.90 (m, 4H); MS m / z 414 (M + Na). l-Benzyloxycarbonyl-4- (4-chloro-2-methylthiophenyl) -piperidine; H NMR (CDC13) d 7.43-7.30 (m, 5H), 7.18-7.10 (m, 3H), 5.16 (s, 2H), 4.42-4.20 (m, 2H), 3.07 (tt, 1H), 3.00-2.80 (m, 2H), 2.47 (s, 3H), 1.91-1.45 (m, 4H); MS m / z 398 (M + Na). l-Benzyloxycarbonyl-4- (4-chloro-2- (R, S) -methylsulfinylphenyl) piperidine; ? E NMR (CDC13) d 7.98 (d, 1H), 7.42 (dd, 1H), 7.41-7.30 (m, 5H), 7.21 (d, 1H), 5.16 (s, 2H), 4.43-4.21 (m, 2H), 2.96-2.78 (m, 3H), 2.71 (s, 3H), 1.92, 1.51 (m, 4H). 4- (4-Chloro-2- (R, S) -methylsulfinylphenyl) piperidine; XH NMR (CDC13) d 7.97 (d, 1H), 7.43 (dd, 1H), 7.28 (d, 1H), 3.30-3.10 (m, 2H), 2.71 (s, 3H), 2.83-2.61 (m, 3H), 1.92-1.51 (m, 5H); MS m / z 258 (M + H).

Example 35 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [4- (2-hydroxy-2-methylpropionamido) -2-methylsulfinylphenyl] -1-piperidinyl] butyl citrate] -N-methyl-3-cyano-2-methoxy-1-naphtamide.

Using standard reductive amination conditions the N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-N-methyl-3-cyano-2-methoxy-1-naphthamide (0.137 g) was made react with 4- [(2-hydroxy-2-methylpropionamido) -2-methylsulfinylphenyl] -piperidine (0.098 g) (prepared from 4- [4- (2-hydroxy-2-methylpropionamido) -2-methylsulfinylphenyl] -N- Cbz-piperidine [Example 31, step (f)] by N-deprotection according to the conditions described for Example 31, step (g)) to achieve the product as a white powder (0.068 g) and converted to the citrate salt. MS: m / z 763 (M +); 1H NMR (DMSO-de) d 9.90-9.80 (m), 8.77-8.60 (m), 8.35-8.22 (m), 8.15-7.98 (m), 7.90-6.75 (m), 6.32 (d), 5.71 (s) , 4.54 (t), 4.15-3.65 (m), 3.60-3.00 (m), 2.98-2.30 (m), 2.25-1.55 (m), 1.35 (s). The required 4- [(2-hydroxy-2-methylpropionamido) -2-methylsulfinylphenyl] -piperidine was prepared as described for example 31.

Example 36 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [4-methoxy- (S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl citrate -3-cyano-2-methylthio-1-naphtamide.

N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [4-methoxy- (S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine (0.270) was combined with 3-cyano-2-methylthio-l-naphthoyl chloride (0.143 g) (prepared from 3-cyano-2-methyl-thiophthoic acid [Example 33] and oxalyl chloride) and triethylamine under standard acylation conditions to achieve a white powder (0.388 g) which was converted to the citrate salt. MS: m / z 708 (M +); XE NMR (DMSO-d6) d 8.78-8.70 (m), 8.17-7.97 (m), 7.86-6.77 (m), 6.42 (d), 4.48 (t), 4.15-3.65 (m), 3.63-2.91 ( m), 2.90-1.50 (m); analysis for C3-7H39Cl2N3? 3S2 »1.0 citric acid» 0.5 H20: calculated; C, 56.76; H, 5.32; N, 4.62; found; C, 56.95; H, 5.26; N, 4.59.

EXAMPLE 37 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulinyl enyl] -1-piperidinyl] butyl] -N-methyl-3 citrate -cyano-2-methylthio-1-naphtamide.

N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methylamine (0.248 g) was combined with 3-cyano-2-thiomethyl-l-naphthoyl chloride (0.145 g) and triethyl amine under standard acylation conditions to achieve a white powder (0.351 g) which was converted to the citrate salt. MS: m / z 678 (M +); 1 H NMR (DMSO-de) d 8.79-8.69 (m), 8.20-8.00 (m), 7.91-6.73 (m), 6.42 (d), 4.48 (t), 4.18 (dd), 3.71 (dd), 3.60 -2.95, (m), 2.94-1.55 (m); analysis for C36H3C12N302S2 * 1.0 citric acid »0.5 H20: calculated; C, 57.33; H, 5.27; N, 4.78; found; C, 57.44; H, 5.26; N, 4.82.

Example 38 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulinylphenyl] -1-piperidinyl] butyl] -N-methyl-3- citrate cyano-2-methylsulfinyl-1-naph amide.

Using standard reductive amination conditions the N- [(S) -2- (3,4-dichlorophenyl) -4-oxobutyl] -N-methyl-2-methylsulfinyl-3-cyano-l-naphthamide (0.213 g) was made react with 4- (2- (S) -methylsulfinylphenyl) piperidine (0.108 g) to achieve the product as a white powder (0.254 g) which was converted to the citrate salt. MS: m / z 694 (M +); XH NMR (DMSO-dβ) d 9.00-8.75 (m), 8.25-8.03 (m), 7.95-6.85 (m), 6.57 (d), 6.43 (d), 4.51 (q), 4.33 (dd), 3.91 -3.80 (m), 3.64 (dd), 3.58-2.31, (m), 2.29-1.58 (m). The required aldehyde was prepared as follows, (a) N- [(S) -2- (3,4-Dichlorophenyl) -4-oxobutyl] -N-methyl-2-methylthio-3-cyano-1-naphthamide. The N- [(S) -2- (3,4-dichlorophenyl) -4-hydroxybutyl] -N-methyl-2-methylthio-3-cyano-l-naphthamide (1.40 g) was reacted with oxalyl chloride and DMSO under standard Swern oxidation conditions in DCM (80 mL) to achieve N - [(S) -2- (3,4-dichlorophenyl) -4-oxobutyl] -N-methyl-2-thiomethyl-3-cyano -l-naphthamide (1.31 g) as a solid after aqueous extraction of DCM and purification by chromatography (10: 1 DCM: EtOAc); MS: m / z 471 (M +); XH NMR (CDC13) d 9.85-9.72 (m), 8.40-8.18 (m), 8.10-7.21 (m), 7.10-6.95 (), 6.92 (d), 6.76 (d), 6.24 (d), 6.54 ( dd), 4.40 (dd), 4.25 (dd), 3.98-3.41 (m), 3.40-2.80 (d), 2.72-2.30 (). (b) N- [(S) -2- (3,4-Dichlorophenyl) -4-oxobutyl] -N-methyl-2-methylsulfini-3-cyano-1-naphthamide. To a solution of N- [(S) -2- (3,4-dichlorophenyl) -4-oxobutyl] -N-methyl-2-methylthio-3-cyano-l-naphthamide (1.31 g) in mL of HOAC was added 4.5 mL of 30% aqueous H202. The mixture was heated at 35 ° C for 2 h, the HOAC was evaporated under reduced pressure, the residue was mixed slowly with mL saturated aqueous NaHCO3. Y was extracted with DCM to give a solid (1.35 g) after purification by chromatography (20: 1 DCM: MeOH); MS: m / z 487 (M +); ? E NMR (CDC13) d 9.85-9.52 (m), 8.60-8.20 (m), 8.18-6.57 (m), 6.61 (d), 6.37 (d), 4.69 (qm), 4.24 (dd), 3.37 (ddd), 4.50-2.40 (m), 2.25-1.80 (m).

Example 39 N- [(S) -2- (3,4-Dichloro-nyl) -4- [4- [4-methoxy- (S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] citrate methyl-3-cyano-2-metisulfinyl-1-naphtamide.

Using standard reductive amination conditions the N- [(S) -2- (3,4-dichlorophenyl) -4-oxobutyl] -N-methyl-2-methylsulfinyl-3-cyano-l-naphthamide (0.215 g) was made react with 4- (4-methoxy-2- (S) -methylsulfinylphenyl) piperidine (0.112 g) to achieve the product as a white powder (0.320 g) which was converted to the citrate salt. MS: m / z 724 (M +); * H NMR (DMSO-dβ) d 9.00-8.78 (m), 8.25-8.03 (m), 7.91-6.80 (m), 6.57 (d), 6.43 (d), 4.51 (q), 4.33 (dd), 3.82 (s), 3.65 (dd), 3.60-2.30, (), 2.29-1.55 (m).

Example 40 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-3-cyano citrate -2-me ilsul onyl-1-naph amide.

Using standard reductive amination conditions the N- [(S) -2- (3,4-dichlorophenyl) -4-oxobutyl] -N-methyl-2-methylsulfonyl-3-cyano-l-naphthamide (0.256 g) (Example 33) was reacted with 4- (2- (S) -methylsulfinylphenyl) piperidine (0.117 g) to achieve the product as a white powder (0.268 g) and converted to the citrate salt. MS: m / z 710 (M +); XH NMR (DMSO-d6) d 9.06-8.83 (m), 8.34-6.80 (m), 6.47 (d), 4.66 (t), 4.17-4.05 (m), 3.63-3.00 (m), 2.98-1.52 ( m); Analysis for C3eH37Cl2N30S2 «l .0 citric acid» 1.0 H20: calculated; C, 54.78; H, 5.04; N, 4.52; found; C, 54.78; H, 5.04; N, 4.52.

Example 41 N- [(S) -2- (3,4-dichloro-enyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-methyl-3- citrate aminocarbonyl-2-methoxy-1-naphthamid.

The N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -l-piperidinyl] butyl] -N-methylamine (0.267 g) was reacted with 3-aminocarbonyl-2-methoxy-1-naphthoic acid (0.288 g) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide and converted to the citrate salt. MS m / z 680 (M +); XH NMR (DMSO-de) d 8.25-8.20 (, 1H), 8.1-6.8 (m, 10H), 6.2 (d, J = 3Hz, 1H), 4.6 (t, J = 10Hz, 1H), 3.8 (s) , 3H), 2.2-1.6 (m, 5H); mp 160-170 (d). The required 2-methoxy-3-carboxamido-l-naphthoic acid was prepared as follows. (a) l-Iodo-2-methoxy-3-naphthoic acid. A solution of l-iodo-2-methoxy-3-carbomethoxynaphthalene (22.2 g) (Example 1) in dioxane (200 mL) was treated with a solution of potassium hydroxide (7.27 g) in water (50 mL) followed by methanol (100 mL). The reaction mixture was stirred for 2 h, diluted with water, acidified with hydrochloric acid and extracted with DCM. The organic layer was dried and concentrated to achieve the product. MS (APCI, negative ion mode) m / z = 328 (M ~). (b) l-Iodo-2-methoxy-3-naphthamide. A solution of l-iodo-2-methoxy-3-naphthoic acid (20.68 g) in DCM was cooled to 0 ° C and treated with 5 drops of DMF followed by oxalyl chloride (11 mL) and the reaction mixture it was stirred at room temperature for 16 h. At the end of this period the reaction mixture was concentrated under reduced pressure, dissolved in THF, cooled to 0 ° C and treated with aqueous ammonia (100 mL). The reaction mixture was diluted with EtOAc, washed with water, dried and concentrated under reduced pressure to achieve the product. MS APCI, m / z = 328 (M +); XH NMR (300 MHz, CDC13) d 8.8 (s, 1H), 8.2 (d, 1H, J = 10Hz), 7.9 (d, 1H, J = 10Hz), 7.6 (m, 2H), 7.5 (m, 1H ), 6 (br, 1H), 3.9 (s, 3H). (c) Methyl 2-methoxy-3-carboxamido-l-naphthoate. A solution of l-iodo-2-methoxy-3-naphthamide (1.57 g) in methanol was treated with palladium acetate (0.108 g), triethylamine (1 mL) and heated under a carbon monoxide atmosphere for 16 h. At the end of this period the reaction mixture was filtered through a pad of celite, concentrated under reduced pressure and purified by chromatography to achieve the product. MS APCI, m / z = 260 (M +); XH NMR (300 MHz, CDC13) d 8.85 (s, 1H), 8.0 (d, 1H, J = 10Hz), 7.8 (d, 1H, J = 10Hz), 7.6 (m, 2H), 7.5 (t, 1H) , J = 10Hz), 6.0 (s, 1H), 4.1 (s, 3H), 4.0 (s, 3H). (d) 2-Methoxy-3-carboxamido-l-naphthoic acid. A solution of methyl 2-methoxy-3-carboxamido-l-naphthoate (0.79 g) in methanol was treated with potassium hydroxide (0.36 g) in water (5 mL). The reaction mixture was heated under reflux for 72 h, diluted with water and extracted with ether. The aqueous layer was acidified with hydrochloric acid and extracted with EtOAc. After drying and concentration under reduced pressure, the desired product was obtained; MS APCI, m / z = 244 (M "); *? NMR (300 MHz, CDC13) d 8.8 (s, 1H), 8.0 (m, 1H), 7.7 (m, 1H), 7.6 (m, 1H) , 7.5 (m, 1H), 4.0 (m, 3H).

Example 42 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -N-ethyl-3-aminocarbonyl citrate -2-methoxy-1-naphtamide.

N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [(S) -2-ethylsulfinylphenyl] -1-piperidinyl] butyl] -N-ethylamine (0.63 g) (Example 10) ) was reacted with 3-aminocarbonyl-2-methoxy-1-naphthoic acid (0.26 g) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, then converted to the citrate salt. MS m / z 694 (M +); XH NMR (DMSO-d6) d 8.25-8.15 (m, 1H), 8.0-6.8 (m, 10H), 6.4 (d, J = 10Hz, 1H), 4.4 (t, J = 10Hz, 1H), 3.8 ( s, 3H), 2.2-1.6 (m, 5H); mp 160-170 (d).

Example 43 N- [(S) -2- (3, -dichlorophenyl) -4- [4- [4-methoxy- (S) -2-methylsulfinylphenyl] -l-piperidinyl] butyl] -3-cyano- citrate 2-methoxy-l-na tamide.

Using standard reductive amination conditions, a mixture of N- [2- (S) - (3,4-dichlorophenyl) -4-oxobutyl] -3-cyano-2-methoxy-1-naphtamide and N- [2- ( S) - (3,4-dichlorophenyl)] -4-oxobutyl-N-carbomethoxymethyl-2-methoxy-3-cyano-l-naphthamide (1.14 g) was reacted with 4- [4-methoxy- (S) - 2-methylsulfinylphenyl] -1-piperidine (0.696 g). The resulting reaction mixture was purified by chromatography to achieve the title compound. MS m / z 678 (M +); XH NMR (CDC13) d 8.2 (s, 1H), 7.8 (, J = 10Hz, 1H), 7.7 (d, J = 10Hz, 1H), 7.6-7.4 (m, 6H), 7.2 (d, d, Jl = 3Hz, J2 = 10Hz, 1H), 6.95 (d, d, Jl = 3Hz, J2 = 10Hz, 1H), 6.7 (d, J = 10Hz, 1H), 5.3 (s, 1H), 4.1 (s, 3H) ), 4.0 (m, 1H), 3.8 (s, 3H), 3.7 (m, 1H), 3.0 (m, 2H), 2.8 (m, 1H), 2.6 (s, 3H), 2.4 (m, 2H) , 2.0 (m, 4H), 1.6-1.2 (m, 6H); mp 120-130 (d). The mixture containing N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-3-cyano-2-methoxy-1-naphthamide and N- [2- (S) - (3, 4-dichlorophenyl)] -4-oxobutyl-N-carbomethoxymethyl-2-methoxy-3-cyano-1-naphthamide was prepared as follows, (a) N- [2- (S) - (3,4-Dichlorophenyl) - 4-hydroxybutyl] -N-carbomethoxymethylamine-3-cyano-2-methoxy-1-naphthalenecarboxamide. A solution of (S) -2- (3,4-dichlorophenyl) -4-hydroxybutylamine (4.68 g) in methanol (50 mL) was treated with 2-hydroxy-2-methoxyacetic acid methyl ester (2.2 mL), acetic acid (2.36 mL) and sodium cyanoborohydride (2.0 g). After stirring for 16 h the reaction mixture was concentrated under reduced pressure, dissolved in DCM and washed with potassium carbonate solution, dried and concentrated to give N- [2- (S) - (3, 4-dichlorophenyl) -4-hydroxybutyl] -N-carbomethoxymethylamine. This material was treated with triethylamine (4.2 mL) and 3-cyano-2-methoxy-1-naphthoyl chloride and dimethylaminopyridine (0.28 g). After stirring for 16 h at room temperature the reaction mixture was diluted with DCM, washed with 5% hydrochloric acid followed by water, dried and concentrated, and purified by chromatography to achieve the title product. MS APCI, m / z = 515 (M +); XH NMR (300 MHz, CDC13) d 8.25 (m, 1H), 7.4 (m, 7H), 4.0 (m, 6H). (b) N- [2- (S) - (3,4-dichlorophenyl) -4-oxobutyl] -N-carbomethoxymethylamine-3-cyano-2-methoxy-1-naphthalenecarboxamide. To a solution of oxalyl chloride (0.76 mL) in DCM (100 mL) at 78 ° C was added DMSO (1.06 mL) followed after 5 min. by a solution of N- [2- (S) - (3,4-dichlorophenyl) -4-hydroxybutyl] -N-carbomethoxymethylamine-3-cyano-2-methoxy-1-naphthalenecarboxamide (3.75 g) in DCM (100 mL ). After 30 minutes the reaction mixture was treated with triethylamine (4.2 mL) and allowed to warm to room temperature. After stirring for 1 hour the reaction mixture was diluted with water and the organic layer was dried and concentrated under reduced pressure to obtain a crude product. Purification by column chromatography provided the desired product. ? E NMR (300 MHz, CDC13) d 9.6 (m, 1H), 8.3 (m, 1H), 7.5 (m, 7H), 4.0 (m, 6H).

Example 44 N- [(S) -2- (3,4-dichlorophenyl) -4- [4- [4-fluoro- (S) -2-methylsulfinylphenyl] -1-piperidinyl] butyl] -3-cyano-2 -methoxy-1-naphtamide.

According to the procedure described for Example 43, the mixture containing N- [2- (S) - (3,4-dichlorophenyl)] -4-oxobutyl-N- (carbomethoxymethyl) -2-methoxy-3-cyano-1 -naphtamide was reacted with 4- [4-fluoro- (S) -2-methylsulfinylphenyl] -1-piperidine to give the product. MS (APCI, negative ion mode) m / z 666 (M-); 1H NMR (CDC13) d 8.2 (s, 1H), 7.8 (d, J = 10Hz, 1H), 7.7 (d, J = 10Hz, 1H), 7.6-7.4 (m, 6H), 7.2 (d, d) = 3Hz, J2 = 10Hz, 1H), 7.1 (m, 1H), 6.8 (, 1H), 5.3 (s, 1H), 4.1 (s, 3H), 4.0 (m, 1H), 3.7 (m, 1H) , 3.0 (m, 2H), 2.8 (m, 1H), 2.6 (s, 3H), 2.4 (m, 2H), 2.0 (, 4H), 1.7-1.2 (m, 6H)); mp 125-140 (d). The required 4- [4-fluoro- (S) -2-methylsulfinylphenyl] -1-piperidine was prepared according to the procedure described in Example 7 except that 2-bromo-5-methoxyphenol was replaced with 2-bromo-5- fluorophenol. fifteen twenty Table 1. Synthesis and experimental data selected for the antagonists Tachykinin. The chiral center of 2-dichlorophenyl-butyl is of the (S) configuration unless otherwise specified. Compounds containing a basic nitrogen were converted to citrate salts.

R3 R4 R ^ ~ R * - R1U MS (m / z) Synthesis Four. Five - . 45 -Me -OMe -CN -H 2- (P (0) (Oet) a) 736 B (1) 46 -. 46 -Me -OMe -CN -H 2- (2-oxazoline) 669 B (2) 47 -. 47 -Me -OMe -CN -H 2- (2-pyridone) 693 B 48 -. 48 -Me -OMe -CN -H 2- (S) -S (0) Me, 4 - F 680 B 49 -. 49 -Me -OMe -CN -H 2-S (0) Me, 4-S (0) Me 724 B fifty - . 50 -Me -OMe -CN -H 2-S (0) Me, 4-OH 678 B 51 -. 51 -Me -OMe -CN -H 2-S (0) Me, 705 B 4-C (0) NH 2 52 * -Me -OMe -CN -H 2- (S) -S (0) Me 662 B 53 -. 53 -Et -OMe -CN -H 4-S (0) Me 676 54 -tBu -OMe -CN -H 2- (S) -S (0) Me 704 A (3) 55 -. 55 -tBu -OMe -CN -H 2- (S) -S (0) e, 734 A (3) 4-Ome RJ go R3 Rb R Ttr MS (m / z) Synthesis 56 -Et OMe -CN -H 2- (R) -S (0) Me 676 A 57 -Et OMe -CN -H 2-S (0) 2Me 692 A 58 -Me O-2-propyl -CN -H 2- (S) -S (0) Me 692 A (4) 59 -Me OMe -Me -H 2- (S) -S (0) Me 651 A (5) 60 -Me OMe -CH2CN -H 2- (S) -S (0) Me 676 A (6) 61 -Me Et -CN -H 2- (S) -S (0) Me, 4-F 678 B 62 -Me Et -CN -H 2- (S) -S (0) Me, 690 B 4 -OMe eo oo 63 -. 63 -Me CH 2 CH (Me) 2 -CN -H 2- (S) -S (0) Me 688 A (7) 64 -Me Et -CN -H 2- (R) -S (0) e 660 B 65 -Me C (CH2) Me -CNH 2- (S) -S (0) Me 672 A (8) 66 -Me Me -CN -OMe 2- (S) -S (0) Me 676 A (10 ) 67 -Me -OMe -CN -OMe 2- (S) -S (0) Me 692 A (11) 68 -Et -OMe -CN -H 2-S (0) Me, 4-OMe 706 A 69 * -cyclopropyl -OMe -CN -H 2- (S) -S (0) Me 688 A (3) A: The compound was prepared by combining the appropriate substituted naphthoyl chloride with the appropriate substituted amine according to the specified standard acylation conditions. B: The compound was prepared by combining the appropriate substituted piperidine with the appropriate substituted aldehyde according to the specified standard reductive amination conditions. FE1 chiral center of 2-dichlorophenyl-butyl has the configuration (R). * This compound is an epimeric mixture containing the (R) and (S) isomers of 2-dichlorophenyl-butyl. (1) The 4- (2-trifluoromethanesulfonyloxyphenyl) -1-N-Cbz-piperidine was reacted with diethylphosphite according to the conditions described by Petrakis, et al .; J. Am. Chem. Soc., 1987, 2831 to provide 4- (2- (diethylphosphono) phenyl) -1-N-Cbz-piperidine which was N-deprotected by hydrogenation to achieve 4- (2- (diethylphosphono) phenyl) -piperidine required. (2) The 4- (2-carboxyphenyl) -1-N-Boc-piperidine was converted to the corresponding hydrochloric acid using oxalyl chloride and reacted with 2-bromoethylamine, according to the conditions described by Elworthy, et al. ., J. Med. Chem., 1997, 2674, to provide the substituted oxazoline. This material was N-deprotected by treatment with 10% TFA in DCM to provide the required 4- (2-oxazolin-2-ylphenyl) -piperidine. (3) The material was prepared by reductive amination of the appropriate substituted cyclopropyl or t-butyl amine with 3, 4-dichloro-alpha-2-propenyl-benzene acetaldehyde (Shenvi, A; Jacobs, RT; Miller, SC; Ohnmacht, CJ; Véale, CA. EP 680962), followed by acylation with the appropriate substituted naphthoyl chloride using standard acylation conditions, then the oxidative cleavage of olefin using sodium periodate, oxidation of the resulting primary alcohol using osmium tetroxide in the corresponding aldehyde , then the reductive amination with the appropriate substituted piperidine. (4) Methyl 3-cyano-2-isopropyloxy-1-naphthoate was prepared by heating methyl 3-cyano-2-hydroxy-1-naphthoate with potassium carbonate and isopropyl bromide in acetone, then saponified to provide the 3-cyano-2-isopropyloxy-1-naphthoic acid. (5) Methyl 2-methoxy-3-methyl-1-naphthoate was prepared by the treatment of 2-hydroxy-3-methoxynaphthalene (Ansink, HR; Zelvelder, E; Cerfontain, H .; Recl. Trav. Chim. Pays- Bas, 1993, 216) with trifluoromethanesulfonic acid, then it was reacted with methyl boronic acid according to Example 15 (c) to give 2-methyl-3-methoxy-naphthalene. This material was treated with N-bromosuccinimide to obtain l-bromo-2-methoxy-3-methyl-naphthalene, then reacted according to the conditions for Example 1 (d). The methyl ester was then saponified to give 2-methoxy-3-methyl-1-naphthoate. (6) Methyl 2-methoxy-3-methyl-1-naphthoate was treated with N-bromosuccinimide in carbon tetrachloride, then reacted with potassium cyanide in ethanol-water, then saponified to give 2-methoxy-3 -cyanomethylnaphthoate. (7) Methyl 3-cyano-2-isobutyl-1-naphthoic acid was prepared according to the procedure described for Example 15, with the exception that 2-methylpropylboronic acid was used instead of methylboronic acid. This material was saponified to achieve 3-cyano-2-isobutyl-1-naphthoic acid. (8) Methyl 3-cyano-2-propenyl-1-naphthoic acid was prepared according to the procedure described for Example 15, with the exception that propenylboronic acid was used in place of methylboronic acid. This material was saponified to obtain 3-cyano-2- (propenyl) -1-naphthoic acid. (10) Ethyl-3-cyano-4-methoxy-2-trifluoromethanesulfonyloxy-1-naphthoate (Example 17) was reacted with methylboronic acid according to the procedure described for Example 15, then saponified to achieve 3-cyano-2 -methyl-4-methoxy-l-naphthoate. (11) Ethyl-3-bromo-2,4-dimethoxy-1-naphthoate (Example 16) was reacted with CuCN according to the procedure for Example 17 (a), then saponified to achieve 3-cyano- 2,4-dimethoxy-l-naphthoic acid. (12) The material of Example 1 was demethylated according to the conditions described for Example 15 (a) to achieve the product. (13) N-Cbz-4- (4-bromo-2- (R, S) -methylsulfinylphenyl) piperidine was prepared according to the procedure described for N-Cbz-4- (4-chloro-2- (R, S ) -methylsulfinylphenyl) -piperidine of Example 34 except that 3-bromophenol was used in place of 3-chlorophenol. This material was reacted with benzyl amine, Cul, and K2C03 in DMF under reflux for 2 hours based on the Wisansky, WA procedure.; Ansbacher, S; J. Am. Chem. Soc .; 1941, 2532, then Cbz-deprotected by heating in TFA at 100 ° C for 2 hours to provide 4- (4-bromo-2-methylsulfinylphenyl) piperidine. (14) Naphtho [2, 3-d] -1,3-dioxol-4-carboxylic acid was prepared according to Dallacker, F; et al .; Z. Naturforsch; 1979, 1434.

Table 2. Experimental data selected for the tachykinin antagonists. The 2-dichlorophenyl-butyl qui i center is of the (S) configuration unless otherwise specified. These materials were prepared using procedures and intermediaries as described in the previous text or elsewhere. Compounds containing a basic nitrogen were converted to citrate salts.

RJ R * RD RD i R 12- MS (m / z) 79 -. 79 -H -0S02Me -CN -H -OH 507 80 -Me -Sme -CN -H -OH 473 81 -Me -S (0) Me -CN -H -OH 489 82 -Me -S02Me -CN -H- OH 505 83 * -Me -OMe -CN -H -OH 457 84 * -Me -OMe -CN -H = 0 455 85 -tBu -OMe -CN -H -OH 499 86 -Me -Et -CN -H- OH 455 87 -Me -OMe -H -H = 0 430 * The giral center of 2-dichlorophenyl-butyl is of the configuration (R) It is noted that in relation to this date, the best method known by the applicant to carry out the present invention is that which is clear from the present description of the invention.

Claims (3)

CLAIMS Having described the invention as above, the content of the following claims is claimed as property:

1. A compound that has the formula characterized in that R1 is oxo, -ORa, -OC (= 0) Rb; or R is H; or R1 is ORc and R2 is -0Rd; or R1 and R2 together form -0 (CH2) mO-; R3 is H or C? _6 alkyl; R 4 is independently selected from hydroxy, halo, C α -6 alkoxy, C α -e alkyl, cyano C α -6 alkyl, C 2 6 6 alkenyl, C 2 -β alkynyl, carboxy, Ci-β alkoxy-carbonyl, carbamoyl, Ci -β alkylcarbamoyl, di-C? -6 alkylcarbamoyl, Ci-e alkanoyl, C? -6 alkanoylamino and aminosulfonyl; R5 is independently selected from hydroxy, cyano, nitro, trifluoromethoxy, trifluoromethyl, C? _ Alkylsulfonyl, halo, C? -6 alkoxy, C? -6 alkyl, cyano C? -6 alkyl, C2_? Alkenyl, C2_? Alkynyl, carboxy , Ci-βalkoxycarbonyl, carbamoyl, C?-Alkylcarbamoyl, di-C ?6 alkylcarbamoyl, Ci-β alkanoyl, C?-6 alkanoylamino, aminosulfonyl, and C?-6 substituted alkyl; or R4 and R5 together form -OCH20- or -OC (CH3) 20-; R6 is selected from hydrogen, hydroxy, cyano, nitro, trifluoromethoxy, trifluoromethyl, Ci-β alkylsulfonyl, halo, C6-alkoxy, C6-6 alkyl, cyano C6-6 alkyl, C2-e alkenyl, C2-β alkynyl, carboxy, C? _6 alkoxycarbonyl, carbamoyl, C? _6 alkylcarbamoyl, di-Ci-β alkylcarbamoyl, C? -6 alkanoyl, C? _6 alkanoylamino, aminosulfonyl, and C? _ substituted alkyl. R7 is substituted phenyl; R8 is selected from hydrogen, hydroxy, C? _6 alkoxy, C? _ Alkanoyloxy, C? -6 alkanoyl, C? -6 alkoxycarbonyl, C? -6 alkanoylamino, C? -6 alkyl, C? -6 carbamoyl, C? -6 alkylcarbamoyl, and bis (C? -6 alkyl) carbamoyl; Ra is hydrogen or C? -6 alkyl; R b is Ci-e alkyl, aryl or aryl Ci-e alkyl; Rc and Rd are independently selected from Ci-βalkyl; m is 2, 3, or 4; and X1 and X2 are independently H or halogen, wherein at least one of X1 and X2 are halogens; and any pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 characterized in that: R1 is oxo, -0Ra, -OC (= 0) Rb; or R1 is -ORc and R2 is -ORd.

3. A compound according to claim 1 characterized in that: R1 is R2 is H. A compound according to claim 3 characterized in that: R7 is substituted in the ortho position by a substituent selected from C? -6 alkylthio, C? -6 alkylsulfinyl, C? -6 alkylsulfonyl, trifluoromethylthio, trifluoromethylsulfinyl, Ci-e alkanesulfonamido, C? _6 alkanoyl, C? -6 alkoxycarbonyl, succinamido, carbamoyl, C? -6 alkylcarbamoyl, di-C? -6 alkylcarbamoyl, C? -6 alkoxy-Ci-e alkylcarbamoyl, C? -6 alkoxy-C? -6 alkylcarbamoyl, C? _6 alkanoylamino, ureido, C? -6 ureido, di-Ci-e alkylureido, amino, C? _6 alkylamino and di-Ci-β alkylamino; and substituted in the para position by a substituent selected from hydrogen, methyl, methoxy, acetyl, acetylamino, methoxycarbonyl, methanesulphonylamino, methylsulfinyl, methylsulfonyl, trifluoromethyl, trifluoromethylthio, trifluoromethylsulfinyl, bromine, fluorine, chlorine, hydroxy, carbamoyl, methylcarbamoyl, dimethylcarbamoyl-methylureido and dimethyluride; and R8 is selected from hydrogen, hydroxy, methoxycarbonyl, methylcarbamoyl and dimethylcarbamoyl. 5. A compound according to claim 4 characterized in that: R7 is methylsulfinyl, methylsulfonyl, methylureido, dimethylureido, amino, methylamino or dimethylamino; R8 is hydroxy or hydrogen; and R9 is hydrogen, C? _6 alkoxy, halo, C? -6 alkylsulfinyl, or carboxy. 6. A compound according to claim 5 characterized in that: R7 is R8 is hydrogen; and R9 is hydrogen, methoxy or fluorine. 7. A compound according to any of claims 2, 3, 4, or 6 characterized in that: R3 is hydrogen, methyl or ethyl; R 4 is C 1-4 alkoxy, C 1-4 alkyl, halogen, halo C? -2 alkoxy, halo C? _4 alkyl, -CH = CHCH 3, -S (0) n CH 3, or -OS (O) 2 CH 3; R5 is cyano, nitrogen, hydrogen or halogen; R6 is hydrogen, methoxy, cyano or nitro; and n is 0, 1 or 2. 8. A compound according to claim 7 characterized in that: R3 is hydrogen, methyl or ethyl; R 4 is methyl, ethyl, methoxy, ethoxy, hydroxy or fluoro; R5 is cyano or nitro; and R6 is hydrogen. 9. A process for the preparation of a compound according to claim 3 characterized in that the process comprises the steps of: reacting a compound of the formula (III) with a compound of the formula (IV) under conditions of reductive amination: (neither: (IV) wherein from R3 to R8, X1 and X2 are as in claim 3; and L and L 'are the reductive amination groups of the formula (III) and (IV) which form an N-C bond; or reacting a compound of the formula (V) with a compound of the formula (VI): (V) (VI) wherein R3 to R8, X1 and X2 are as defined in claim 3; and L "is a leaving group. 10. A pharmaceutical composition characterized in that it comprises a compound according to any of claims 1 to 8.